UNITED STATES


SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K/A

(Amendment No. 1)
10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)


OF THE SECURITIES EXCHANGE ACT OF 1934

(Mark One)

RANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended June 30, 2010


OR

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from          to
2012

Commission File Number:file number 0-29901

Cavitation Technologies, Inc.


(Exact name of Registrant as Specified in its Charter)

Nevada
20-4907818
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification No.)


10019 CANOGA AVENUE, CHATSWORTH, CALIFORNIA    91311


(Address, including Zip Code, of Principal Executive Offices)

Offices )

(818) 718-0905


(Registrant’s telephone number, including area code)
Registrant's Telephone Number, Including Area Code)


SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
Title of Each Class:Name of Each Exchange on Which Registered:
NoneOver the Counter (Bulletin Board)

SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:


Common Stock, $0.001 par value

Title of Each Class:

Name of Each Exchange on Which Registered:

Common Stock, $0.001 par value

Over the Counter (Bulletin Board)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesYES   ¨      No        NO   x


Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YesYES   ¨     No R        NO   x


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d)15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesYES   R     Nox        NO   ¨


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     YesYES  ¨x     NO        No ¨


Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.101 of this chapter) is not contained herein, and will not be contained, to the best of registrant’sregistrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K, or any amendment to this Form 10-K.   R¨


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large"large accelerated filer,” “accelerated filer”" "accelerated filer" and “smaller"smaller reporting company”company" in Rule 12b-2 of the Exchange Act. (Check one):


Large Accelerated Fileraccelerated filer   ¨

Accelerated Filerfiler   ¨

Non-Accelerated Filer

Non-accelerated filer   ¨
(Do not check if a smaller reporting company)

Smaller Reporting Companyreporting company   Rx


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes
YES   ¨     No R        NO   x

State the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant by reference to the price at which the common equity was last sold, or of the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completely second fiscal quarter: $26,216,684$4,849,113 as of December 31, 20092011 based on the closing price of $0.23$0.04 per share and 70,186,388121,227,836 non-affiliate shares outstanding.


The registrant had 133,690,665168,782,063 shares of common stock outstanding September 28, 2010.


Documents incorporated by reference: None.

EXPLANATORY NOTE
This Amendment No. 1 on Form 10-K/A (the “Amendment”) amends the Annual Report on Form 10-K for Cavitation Technologies, Inc., referred to herein as the “Company,” “we,” “us" or “our” as initially filed with the Securities and Exchange Commission (“SEC”) on September 28, 2010 (the “Original Report”) for the fiscal year ending June 30, 2010. The Company is filing this Amendment for the purpose of amending and supplementing: Item 1. Business; Item 9A(T). Controls and Procedures; Item 11. Executive Compensation; Item 15. Exhibits, Financial Statement Schedules.

All other items presented in the Original Report are unchanged. This Amendment does not reflect events occurring after the date of the Original Report or modify or update any of the other disclosures contained therein in any way other than the amendments referred to above. Accordingly, this Amendment should be read in conjunction with the Original Report and the Company’s other filings with the SEC.

In addition, as required by Rule 12b-15 of the Securities Exchange Act of 1934, this Amendment contains new certifications by our Principal Executive Officer and our Principal Financial Officer, filed as exhibits hereto.

This 10-K/A reflects all share numbers with regard to the 3 for 1 forward split which occurred October 12, 2009.
2
24, 2012.

DOCUMENTS INCORPORATED BY REFERENCE:

None.




CAVITATION TECHNOLOGIES, INC.


FORM 10-K/A10-K ANNUAL REPORT

FOR THE YEAR ENDED JUNE 30, 2010
2012
TABLE OF CONTENTS

  Page
PART I  
Item 1. Business 4
Item 1A. Risk Factors7
Item 1B. Unresolved Staff Comments7
Item 2. Properties7
Item 3. Legal Proceedings7
Item 4. Mine Safety Disclosures7
   
PART II  
Item 9A(T).5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities8
Item 6. Selected Financial Data9
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations9
Item 7A. Quantitative and Qualitative Disclosures About Market Risk14
Item 8. Financial Statements and Supplementary Data15
Item 9 Changes In and Disagreements With Accountants on Accounting and Financial Disclosure38
Item 9A. Controls and Procedures 738
Item 9B. Other Information39
   
PART III  
Item 10.10 Directors, Executive Officers and Corporate Governance 840
Item 11.11 Executive Compensation 942
Item 13.12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters44
Item 13 Certain Relationships and Related Transactions, and Director Independence 1045
Item 14 Principal Accounting Fees and Services46
   
PART IV  
Item 15.15 Exhibits, Financial Statement Schedules 1046
   
Signatures 1348

3



PART I

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS


This annual report on Form 10-K and the exhibits attached hereto contain “forward-looking”"forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements concern our anticipated results and developments in our operations in future periods, planned exploration and development of our properties, plans related to our business and matters that may occur in the future. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. We use words like “expects,” “believes,” “intends,” “anticipates,” “plans,” “targets,” “projects”"expects," "believes," "intends," "anticipates," "plans," "targets," "projects" or “estimates”"estimates" in this annual report. When used, these words and other, similar words and phrases or statements that an event, action or result “will,” “may,” “could,”"will," "may," "could," or “should”"should" result, occur, be taken or be achieved, identify “forward-looking”"forward-looking" statements. Such forward-looking statements are subject to certain risks and uncertainties, both known and unknown, and assumptions.


Our management

Management has included projections and estimates in this annual report, which are based primarily on management’smanagement's experience in the industry, assessments of our results of operations, discussions and negotiations with third parties and a review of information filed by our competitors with the Securities and Exchange Commission or otherwise publicly available. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as required by law. We qualify all the forward-looking statements contained in this annual report by the foregoing cautionary statements.


PART I

ITEM 1.  BUSINESS


The following discussion includes forward-looking statements, including but not limited to, management’s expectations of competition; revenues, margin, expenses and other operating results or ratios; operating efficiencies; economic conditions; cost savings; capital expenditures; liquidity; capital requirements; acquisitions and integration costs; operating models; exchange rate fluctuations and rates of return. We disclaim any duty to update any forward-looking statements.

Introduction

Hydrodynamic Technology, Inc. was incorporated January 29, 2007 as a California corporation. It is a wholly owned subsidiary of Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as “the Company,” “CTi,” “we,” “us,”the "Company," "CTi," "we," "us," and “our”"our") a Nevada corporation originally incorporated under the name Bio Energy, Inc. Cavitation Technologies, Inc. ("the Company")The Company engineers and designs and engineers environmentally friendly NANONano technology based systems. These systems that have potential commercial applications in markets such asindustrial liquid processing.CTi is a California-based development stage company that has designed, developed, and patented two proprietary Nano Reactors (Nano Reactor®). In addition, the company has filed a number of process patent applications incorporating these patented devices for processing fluids in vegetable oil refining, renewable fuels,waste water purification, alcoholic beverage enhancement,treatment, algae oil extraction, and crude oil yieldalcoholic beverage enhancement.


Our investment in research and development (R&D)("R&D") since inception on January 29, 2007 through June 30, 20102012 is $4,623,400 most of which is$5,440,396 in the form of shares issued to service providers.total and $152,002 and $664,994 for fiscal years 2012 and 2011 respectively. This investment in R&D has led to potential commercial products includingtwo device patents issued for the Green D+Plus NANO Neutralization System – a vegetable oil refining system, and the Bioforce 9000 NANO Reactor System which performs transesterification during the production of crude biodiesel. Both the Green D+ PlusSystem and the Bioforce 9000NANO Reactor System employ our proprietary, continuous flow-through, hydrodynamic NANO Technology in the form of our multi-stage NANO Series of reactors. Our reactor process can create particles in some cases smaller than one micron (nano particles) and bond these particles at the molecular level. The Reactor has no moving parts, operates continuously, and is easily scalable to high volumes. To dateCompany'sNano Reactor®. In addition, the Company has sold no productsfiled fluid process patents and has recorded no revenue from product sales.

4


commercializedCTi Nano Neutralization®in the refining process of certain vegetable oils which has proven to reduce costs and increase yields for our customers

Vegetable Oil Refining


The Company's first commercial application for its technology isCTi Nano Neutralization®. Our Green D+ Plus NANO Refining System uses a patented NANO Refining Technology thatenvironmentally friendly process has proven to reduce refining costs, increase oil yield, and limit the amount of chemical additives used in chemical refining vegetables oils. This patent pending process is designed to be used in the vegetable oil refining process to refine crude or de-gummed vegetable oils such asincorporated into new and existing soybean, rapeseed, and canola into high quality de-gummedoil chemical refineries. The global demand for vegetable oils has grown consistently at lower costs.


Distribution Methods

We intenda rate of about 5.5% p.a. from 84.5 million metric tons in 1999 to license150.8 million metric tons in 2011.

The Company's first pilot test of our technology/systems globally throughNANO Neutralization System was conducted 2010 at Carolina Soya, a distribution network of strategic partners who are recognized leaders200 metric ton/day crude soy oil refining plant in their field and who design, build, install and recommend our systems. In January 2010Estill, South Carolina. Our second system which became operational in fiscal 2011 is a 450 metric tons per day (mtpd) plant that has been in continuous operation for more than 18 months. A third plant (50 tons per day has been operating in North Carolina since February 2012.

4


Desmet Ballestra Agreement

On May 14, 2012 we signed a globalR and D, Marketing and Technology License Marketing & Collaboration Agreementwith the n.v. Desmet Ballestra Group s.a. (Desmet) who will market our Green D + Plus, a Belgian company that is actively marketing theNANO Neutralization System ,the key component of which is the Company's reactor to soybean and other vegetable oil refiners. The Agreement provides Desmet (licensee) a limited, exclusive license and right to develop, design and supply Nano Refining System. Salient termsReactor® systems which incorporate Nano Reactor® devices on a global basis but is limited to oils and conditionsfats and oleo chemical applications. CTi (licensor) remains owner of the agreement include: 1. We as licensor will grant licenses to Desmet (licensee), for use of the Green D + Plus Nano Refining technology. 2.current patents and patent applications but Desmet will be co-owner of any new process patent applications jointly developed. Desmet has agreed to provide, under certain conditions, limited monthly advance payments of $125,000 against future sales to CTi. Desmet shall be entitled to immediately terminate the primary interface withpresent agreement in case the end-user (site user). 3.claims of current US Patent Application Number 12/484,981 are not granted as such or are cancelled. In order to maintain exclusivity,addition, Desmet must license a minimum number of units in each of the first three years of the agreement. 4. The performance test conducted by Cavitation Technologies, Inc. with regard to each system/license must demonstrate during a test period that the system’s performance achieved contractual performance. 5. For services provided, we will pay Desmet a variable commission. 6. The initial term ofmay terminate the agreement is three yearson August 1 of any particular year if they have not installed at least 6 Nano Reactor® devices in the previous 12 month period. CTi may terminate the Agreement for material default. This Agreement supersedes a previous agreement dated November 1, 2010, amended on June 1, 2011 and will automatically extend provided on September 2, 2011.

Desmet, meets the terms of the agreement. The agreement is currently in good standing. Article 9.01(b) describes the minimum number of units to be purchased and Article 7.01(b) describes the variable commission. As a result of the November 2010 agreement, the minimum number of units remains unchanged while the variable commission increased.


Desmettogether with its affiliates, is a global leaderengineering and equipment supply firm engaged in providingthe development, design and supply of process equipment tofor oils and fats processing facilities including vegetable oil refining, biofuel, oleo chemical, seed crushing, surfactant and detergent markets. Desmet supplies these markets with competitive services based on the approximate $70B/yr. edible oil extraction and refining industry.latest globally sourced technologies. Since its founding in 1946, Desmet has built a global network that includes 1,300 employees, 17 global and 8 representative offices, and more than 5,700 lines in a variety of applications. Specifically, Desmet will manageoperates a separate division for each of the globalabove markets and the Desmet Oils & Fats division has supplied small and large plants to approximately 1,700 oil millers in 150 countries, covering over 6,000 process sections. We have developed a relationship with the North American arm of Desmet which operates in each of these markets and provides the Company with other potential opportunities such as palm oil refining.

The Company and Desmet have worked together to determine the appropriate sales approach and installation process. The Company's Nano Neutralization is designed to be used as an add-on process to an existing neutralization system within soybean and other vegetable oil refineries. Desmet is now focused on marketing sales, CTi's Nano Neutralization® to vegetable oil refiners to help them increase profits through cost savings and project executionimproved oil yields. Desmet purchases Nano Reactor Systems from the Company and installs them at the refinery as part of our Green D + Plusan integrated neutralization system. Based on successful commercial implementations, Desmet guarantees minimum economic benefits to a facility that installs CTi Nano Refining SystemsNeutralization®. We rely exclusivelyare therefore substantially dependent on our strategic partnership with Desmet to market,identify prospects, complete sales contracts, install the system and distribute our products to new customers. We will focusmanage relationships with end-users. CTi focuses on developing additional Nano ReactorReactor® applications and managing the intellectual property issues associated with these new developments.

Desmet also presents ushas relationships with potential opportunitiesmajor refiners globally A significant portion of global vegetable oil refineries include major refiners such as Archer Daniels Midland Company, Cargill, Inc. and Bunge Limited. Desmet has more than 40 sales representatives selling in the palm oil industryNorth America, South America, Europe, and in enzymatic refining.


In April 2010 we signed a memorandum of understandingAsia.

Customers

We have an exclusive sales and marketing agreement with aon our strategic partner, Desmet Ballestra, to marketCTi Nano Neutralization®. and other applications to the vegetable oil refining plant located in Minnesotaindustry. We sell our Nano Reactors and technology to Desmet and they are responsible for pilot testing a 40 GPM NANONeutralization System on a production line that processes 200 ton/day of de-gummed oil. The material termsinstalling and conditions ofservicing the memo included: 1. The plant was to conduct a test to demonstrate the ability of our system to significantly reduce operating costs in soybean oil refining. 2. The Minnesota plant pays all costs of installation. 3. We have the right to access the equipment, operating data, and to collect pre-process and post-process samples. 4. We received a small one-time payment of $15,000.00 to cover use of our equipment. 5. The agreement terminated May 24, 2010. We are discussing a potential sale with this company.


Customers

We have one customer. In June 2010 we completed a pilot test of our 40 GPM NANO Neutralization System at a 200 tons/day commercial crude vegetable oil refining plant in South Carolina. The system has been integrated and is operating at the plant. We have received monthly payments of $5,000.00 from this facility for use of our system since May 2010. Because there is no written agreement with this client, amounts received were recorded as Deferred Revenue in our balance sheet as of September 30, 2010. The company is uncertain as to how long these payments will continue. Although there is no written agreement, our understanding of the material elements of this verbal agreement are that this facility will continue to pay us $5,000 monthly for the continued use of our system. The amount was based on the rental value of the equipment. The amount is expected to remain unchanged as long as we continue to receive payments which is uncertain.

The global target market for our Green D+ Plus System includes approximately 300 major (greater than 200 tons per day processing capability) vegetable oil refining plants. The global demand for processed vegetable oils has grown consistently from 84.7 million metric tons in 1999 to 126 million metric tons in 2008.
systems.

5



Biodiesel

Our fully automated Bioforce 9000 NANO Reactor Skid System performs the transesterification process during the production of biodiesel; that is, it fully converts all mono-, di-, and tri-glycerides contained in feedstock (such as animal fats and vegetable oils) into methyl esters (crude biodiesel). Given the conditions of the global biodiesel market and given the limited resources of our company, we do not intend to focus significant resources to the development of this market in the foreseeable future. Instead, we plan to focus the bulk of our resources on developing our Green D+ Plus line of business.

Sources and availability of raw materials and the names of principal suppliers


We have historically sourced reactor components from various domestic and international suppliers including Canyon Engineering and Strategic IR with whom we have no long term contracts, agreements, or commitments. They provide parts as directed. We believe it would take approximately 60 days to find a new supplier, if necessary.


Competition


We have

Our competitors who sell equipment and engineering services for the vegetable oil refining business are a varietymyriad of competitors,companies both large and small.small that provide equipment and technology to oil refiners. These include known companies that have longer operating histories, more experience, and stronger financial capabilities. Competitors include Westfalia, Alfa Laval, and Crown Iron Works as well as many firms that provide advice and services to small and regional firms. In addition, Arisdyne Systems, a designer of cavitation devices, is marketing a system using similar technology. The markets in which we intend to compete arevegetable oil refining business is a highly competitive commodity marketsmarket where the low-cost producer has the advantage. CompetitorsWe intend to compete by offering solutions that help our clients remain or become a low-cost producer. Because the industry in which we compete has limited new technology introduced in the edible oil refining industry include well-known companies which have longer operating histories and stronger financial capabilities than we.last 50 years, we believe theCTi Nano Neutralization® provides a unique opportunity for refiners to increase margins. We differentiate ourselves by the designs, processes, and applications described in our approvedissued and patent and patents pending applications. We intend to compete by offering solutions that we believe can reduce operating expenses and increase yield vis-à-vis current technology.

Patents

OurCavitation Generator patent was issued during fiscal 2011. In addition, we have a patent for ourMulti-State Cavitation Device that was issued August 22, 2011.

We also have eight US and eight PCT/ international patent applications pending which apply to the design of the Company's reactor and the processes related thereto. The Company filed a number of process patent applications incorporating these patented devices for processing fluids in vegetable oil refining, waste water treatment, algae oil extraction, and alcoholic beverage enhancement. We received comments from the USPTO with regard to our Method for Cavitation-Assisted Refining, Degumming, and Dewaxing of Oil and Fat, and we responded. We also received a second round of comments and are responding to those as well. There is no assurance that our patents pending will be ultimately issued.

The Company believes its technology can be applied to other liquid processing industries where there is a need to solve environmental problems, reduce operating costs, and/or improve quality and helpyield. The Company's issued and allowed patents and pending patents support potential applications of the Company's proprietary technology in markets which include, but are not limited to, vegetable oils refining, renewable fuel production, alcoholic beverage enhancement, water purification, and algae oil extraction. In addition, we believe our clients remain or become a low-cost producer.


Patents

proprietary technology may also be applied to fuel mixing and crude oil refining. During fiscal 2011, we received the "CE Marking" certification which allows us to market our systems in the European Union.

Our success will depend in part on our ability to obtain patents, maintain trade secrets, and operate without infringing on the proprietary rights of others both in the United States and other countries. Our Cavitation Generator patent was issued during fiscal 2011, and is being amortized over an estimated useful life of four years. The patent has a duration through February 27, 2029. In addition, we have nine US and nine PCT/ international patent applications pending which apply to the design of the Company’s Reactor and the processes related thereto. We plan to continue to apply for new and improved patents on a regular basis. Our approved patent and patents pending apply to potential commercial applications in markets such as vegetable oil refining, renewable fuels production, water purification, crude oil yield enhancement, and alcoholic beverage enhancement. There can be no assurances that patents issued to the CompanyCTi will not be challenged, invalidated, or circumvented, or that the rights granted hereunder will provide proprietary protection or competitive advantage to CTi. We plan to continue to invest in R&D and file for new and improved patents.

Royalty Agreements

On July 1, 2008, our wholly owned subsidiary entered into Patent Assignment Agreements with two individuals, our President as well as our former CEO/current CTO, where certain devices and methods involved in the hydrodynamic cavitation processes invented by these two individuals were assigned to the Company. In exchange, the Company


agreed to pay a royalty of 5% of gross revenues to each of these two individuals for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assigned to Cavitation Technologies on May 13, 2010.  The Company's CTO and President both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through June 30, 2012.

6


On April 30, 2008 (as amended November 22, 2010), our wholly owned subsidiary entered into an employment agreement with the Director of Chemical and Analytical Department ("Inventor") who shall receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year.

Governmental Approval and Regulations and Environmental Compliance


Due to the nature of our products, we have incurred no costs with respect to environmental compliance with federal, state, and local laws. To our knowledge, our products do not require governmental approval, and we do not foresee that governmental regulations will have a material impact on our business.

New Partner

In August 2012 the Company entered into aTechnology and Licensing Agreement with the GEA Group AG - Westfalia Separator Group GmbH, Oelde, Germany (GEA Westfalia). The companies have agreed to jointly develop and patent new process applications for CTi's Nano Reactor® ®. As part of the Agreement, GEA Westfalia will assemble a complete commercial system incorporating CTi technology in their facility. This will facilitate the testing of existing processes that have been developed by CTi and the joint development of new process applications. GEA Westfalia is a leading worldwide supplier of process equipment to industries including dairy and beverage.

Employees

On June 30, 2012 we had six total and full-time employees and had engaged approximately 5 consultants and independent contractors over the past year. Members of our staff and technical team are comprised of experienced professionals who are chemists, civil-, chemical-, and mechanical engineers with expertise in hydrodynamic cavitation, nano technology, water treatment, and biotechnology. These individuals hold Ph.Ds in Chemistry and Biology as well as degrees in Civil, Chemical, and Mechanical Engineering.

ITEM 1A.  RISK FACTORS

Not applicable for smaller reporting companies.

ITEM 1B.  UNRESOLVED STAFF COMMENTS

None.

ITEM 2.  PROPERTIES

Our corporate headquarters is located in Chatsworth, California. This approximate 5,000 square foot facility includes office space and an area to conduct research and development.  We extended our lease agreement for office space until February 1, 2013.  We do not anticipate any material difficulties with the renewal of our rental agreement when it expires or in securing replacement facilities on commercially reasonable terms.

ITEM 3.  LEGAL PROCEEDINGS

We know of no material, existing or pending legal proceeding against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings known to us in which any of our directors, officers or affiliates is an adverse party or has a material interest adverse to our interest.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

7


PART II

ITEM 5.  MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Common Stock

Our Common Stock is traded on the Over the Counter Bulletin Board under the symbol CVAT. The following table sets forth the high and low price per share based on the closing price of our Common Stock for the periods indicated.

 

 

 

HIGH

 

 

LOW

 

 

 

 

 

 

 

 

 

 

 

Fiscal 2012

First Quarter

 

$

0.10

 

 

 

0.05

 

 

Second Quarter

 

 

0.06

 

 

 

0.03

 

 

Third Quarter

 

 

0.05

 

 

 

 0.03

 

 

Fourth Quarter

 

 

0.05

 

 

 

0.02

 

 

 

 

 

 

 

 

 

 

 

 

HIGH

 

 

LOW

 

 

 

 

 

 

 

 

 

 

 

Fiscal 2011

First Quarter

 

$

0.19

 

 

 

0.13

 

 

Second Quarter

 

 

0.15

 

 

 

0.10

 

 

Third Quarter

 

 

0.15

 

 

 

 0.09

 

 

Fourth Quarter

 

 

0.12

 

 

 

0.09

 

We became a public company through a share exchange that was effected in October 2008. The first day of public trading of our stock was November 11, 2008.  Since our fiscal year end was changed to June 30, public trading of our stock began in the second quarter of fiscal 2009.  As of September 20, 2011, there were approximately 1100 holders of record of our Common Stock.  This does not reflect the number of persons or entities who hold stock in nominee or "street" name through various brokerage firms.

Dividend Policy

We have neither declared nor paid any dividends on our Common Stock in the preceding two fiscal years. We currently intend to retain future earnings to fund ongoing operations and finance the growth and development of our business and, therefore, do not anticipate declaring or paying cash dividends on our Common Stock for the foreseeable future. Any future decision to declare or pay dividends will be at the discretion of the Board of Directors and will be dependent upon our financial condition, results of operations, capital requirements, and such other factors as the Board of Directors deems relevant. In addition, certain of our debt facilities contain restrictions on the declaration and payment of dividends.

Securities Authorized for Issuance under Equity Compensation Plans

None

Unregistered Sales of Equity Securities and Use of Proceeds

Since our previous disclosure in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, filed on May 16, 2012, the following is our unregistered security activity.

8


Issuance of Common Stock for Conversion of Debt

On April 3, 2012, we issued 60,096 shares of common stock to Gel Properties, LLC, an accredited investor, as conversion of $1,000 of outstanding convertible notes. On April 17, 2012, we issued 60,332 shares of common stock to Gel Properties, LLC as conversion of $1,000 of outstanding convertible notes. On April 19, 2012, we issued 66,365 shares of common stock to Gel Properties, LLC as conversion of $1,100 of outstanding convertible notes. On April 23, 2012, we issued 267,559 shares of common stock to Gel Properties, LLC as conversion of $4,800 of outstanding convertible notes. On April 23, 2012, we issued 113,311 shares of common stock to Gel Properties, LLC as conversion of $2,033 of accrued interest. On June 6, 2012, a conversion request was submitted by the Prolific Group, LLC for $21,450 of outstanding convertible notes corresponding to 1,500,000 shares of common stock. These shares were subsequently returned to the Company in the first quarter of fiscal 2013, and the note of $25,000 was paid in full in two payments of $15,000 on July 12 and $10,000 on August 7 plus a pre-payment premium of $12,500. These shares were issued in reliance on Section 4(2) of the Securities Act of 1933, as amended . These shares were not offered via general solicitation to the public.. No sales commissions or other remuneration was paid in connection with these issuances.

Issuance of Common Stock for Services

On June 3, 2011, we issued 200,000 shares of common stock with a recorded value of $4,629 to Tripod Group, LLC, an accredited investor, as a break-up fee for a financing arrangment. The shares were issued in reliance on Section 4(2) of the Securities Act of 1933, as amended. The shares were not offered via general solicitation to the public . The Company issued rule 144 shares in connection with these issuances. No sales commissions or other remuneration was paid in connection with this issuance.

ITEM 6.  SELECTED FINANCIAL DATA

Not applicable for smaller reporting companies.

ITEM 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of should be read in conjunction with the Company's financial statements and the related notes. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as its plans, objectives, expectations and intentions. Its actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements.

Overview of Our Business

Hydrodynamic Technology, Inc. was incorporated January 29, 2007 as a California corporation. It is a wholly owned subsidiary of Cavitation Technologies, Inc., a Nevada corporation originally incorporated under the name Bio Energy, Inc. We design and engineer environmentally friendly technology based systems that are designed to serve large, growing, global markets such as vegetable oil refining, renewable fuels, water treatment, algae oil extraction, water-oil emulsions and crude oil yield enhancement.  Our systems are designed to process industrial liquids at a lower cost and higher yield than conventional technology. We are a process and product development firm that has developed, patented, and commercialized proprietary technology

CTi has developed, patented, and commercialized proprietary technology that can be used for processing of industrial fluids. CTi's patentedNano Reactor® is the critical components ofthe CTi Nano Neutralization® System which is commercially proven to reduce operating costs and increase yields in processing oils and fats. CTi has two issued patents relating to ourNano Reactor® systems and has filed several national and international patents to employ its proprietary technology in applications including, vegetable oil refining, waste water treatment, algae oil extraction, and alcoholic beverage enhancement.

9


During the year ended June 30, 2012, we recorded revenue of $187,216. Our cumulative loss since inception on January 29, 2007 is $18,597,791 including $11,666,060 in common stock issued for services. Cumulative net cash used in operating activities of $3,652,351 was funded largely with $4,229,699 in cash from financial activities including proceeds of $725,000 from the sale of preferred stock, $471,212 from the sale of convertible notes, $2,139,690 from the sale of common stock and $349,276 in a bank loan.  

Management's Plan of Operation

As a Development Stage company, we present aPlan of Operation for the next twelve months. We are engaged in merchandising ourNeutralization System which is designed to help refine vegetable oils such as soybean, canola, and rapeseed.  Our near term goal is to continue to merchandise our systems through our partner, Desmet Ballestra. We have not generated significant revenue and, from January 29, 2007, (inception), through June 30, 2012, generated a net loss of $18,597,791.  We also have negative cash flow from operations and negative net equity. The accompanying financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going concern.

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going concern. The Company has not generated significant revenue and from January 29, 2007, (inception) through June 30, 2012 recorded cumulative revenue of $777,142 and a cumulative net loss of $18,597,791. To date, cumulative negative cash flow from operations of $3,652,351 was funded largely with $2.8 million in equity. Total Stockholder's Deficit at June 30, 2012 was $1,963,972.

Management's plan is to generate income from operations by licensing our technology globally through our strategic partner, the Desmet Ballestra Group. Desmet has agreed to provide us limited advance against sales payments. As of June 30 and August 30, 2012, cumulative advances received amounted to $125,000 and $375,000 respectively. These funds pay maturing debt plus a portion of operational expenses on a monthly basis. Desmet shall be entitled to immediately terminate the present agreement in case the claims of current US Patent Application Number 12/484,981 are not granted as such or are cancelled. In addition, Desmet may terminate the agreement on August 1 of any particular year if they have not installed at least 6 Nano Reactor® devices in the previous 12 month period. CTi may terminate the Agreement for material default. This Agreement supersedes a previous agreement dated November 1, 2010, amended on June 1, 2011 and on September 2, 2011. In addition to these advances, we anticipate that we will need additional funding, and we will attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company's needs, or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations. For a more detailed discussion of our plan, please review to Part I, Item 1,Business.

The accompanying consolidated financial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from an inability of the Company to continue as a going concern. As a result of the aforementioned factors, our independent auditors, in their report on our audited financial statements for the fiscal year ended June 30, 2012, expressed substantial doubt about our ability to continue as a going concern.

Critical Accounting Policies and Revenue Recognition

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses. The accounting policies and estimates described below are those CTi considers most critical in preparing its consolidated financial statements. The following is a review of the accounting policies and estimates that include significant judgments made by management using information available at the time the estimates are made. However, these estimates could change materially if different information or assumptions were used instead.

10


Note 3 to the financial statements includes a summary of significant accounting policies, estimates, and methods used in the preparation of CTi's financial statements. Accounting estimates are an integral part of the preparation of financial statements and are based on judgments by management using its knowledge and experience about the past and current events and assumptions regarding future events, all of which we consider to be reasonable. These judgments and estimates reflect the effects of matters that are inherently uncertain and that affect the carrying value of our assets and liabilities, the disclosure of contingent liabilities and reported amounts of expenses during the reporting period.

Revenue Recognition

Revenue from the sale of ourNano Reactor® Systems is recognized when persuasive evidence of an agreement exists; delivery has occurred, including transfer of title and risk of loss for product sales, or services have been rendered for service revenues; the price to the buyer is fixed or determinable; and collectability is reasonably assured. The Company employs the Milestone Method of Revenue Recognition. Accounting Standard Codification 605-28-15 describes the Milestone Method as pertaining to R&D deliverables under which the Company satisfies its performance obligations over a period of time and which a portion or all of the consideration is contingent upon uncertain future events or circumstances. Revenue from the licensing of ourNano Reactor® System includes non-refundable license fees that are triggered upon achievement of a specific event. For agreements that provide for milestone payments, such as our agreement with Desmet Ballestra, we adopted ASC 605-28-25, Revenue Recognition, Milestone Method.

Recoverability of Intangible and Long-Lived Assets

Management believes that the accounting estimate related to the recoverability of its intangible and long-lived assets is a "critical accounting estimate" because significant changes in the assumptions used to develop the estimates could materially affect key financial measures, including net income and non-current assets.

Testing intangible and long-lived assets for impairment involves a high degree of judgment due to the assumptions that underlie the undiscounted cash flows analysis. In accordance with ASC 350-30, we evaluated long-lived assets for impairment whenever events or changes in circumstances indicate that the net book value may not be recoverable. When such factors and circumstances exist, we compare the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amount. Impairment, if any, is based on the excess of the carrying amount over the fair value based on market value when available or discounted expected cash flows of those assets and is recorded in the period in which the determination is made. Management believes there is no impairment of its long-lived assets. There can be no assurance, however, that market conditions will not change or demand for our products under development will continue. Either of these could result in future impairment of long-lived assets.

Share-Based Compensation

We account for our share-based compensation in accordance ASC 718-20. Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite vesting period. 

Determining the fair value of share-based awards at the measurement date requires judgment, including estimating the expected term that stock options and warrants will be outstanding prior to exercise, the associated volatility, and the expected dividends. CTi estimates the fair value of options granted using the Black-Scholes valuation model. The expected life of the options used in this calculation is the period the options are expected to be outstanding and has been determined based on historical exercise experience. Expected stock price volatility is based on the historical volatility of CTi's stock for a period approximating the expected life, and the risk-free interest rate is based on the implied yield available on US Treasury zero-coupon issues approximating the expected life. Judgment is also required in estimating the amount of share-based awards that will be forfeited prior to vesting. CTi believes that these assumptions are "critical accounting estimates" because significant changes in the assumptions used to develop the estimates could materially affect key financial measures including net income/(loss).

11


Income Taxes

Management believes that the accounting estimate related to income taxes is a "critical accounting estimate" because significant judgment is required in interpreting tax regulations in the US, evaluating CTi's uncertain tax positions, and assessing the likelihood of realizing certain tax benefits. Actual results could differ materially from those judgments, and changes in judgments could materially affect CTi's consolidated financial statements.

We account for income taxes in accordance with ASC 740-10. We recognize deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at expected future tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates on the date of enactment. 

ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. We measure and record uncertain tax positions by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.

In the normal course of business, CTi may be audited by federal and state tax authorities. The ultimate settlement of any particular issue with the applicable taxing authority could have a material impact on CTi's financial statements.

Results of Operations

As a Development Stage Enterprise, we have provided aPlan of Operation herein. Although there is no obligation for a Development Stage Company to provide a discussion of Results of Operations, below is an abbreviated summary comparing fiscal 2012 and fiscal 2011.

    For the Years Ended     
    June 30,     
    2012  2011  $ Change % Change
             
Revenue  $187,216  $589,926  $(402,710) -68.3%
Cost of revenue   40,564   91,144   (50,580) -55.5%
     Gross profit   146,652   498,782   (352,130) -70.6%
General and administrative expenses   1,720,315   3,029,912   (1,309,597) -43.2%
Research and development expenses   152,002   664,994   (512,992) -77.1%
Total operating expenses   1,872,317   3,694,906   (1,822,589) -49.3%
     Loss from operations   (1,725,665)  (3,196,124)  1,470,459  -46.0%
Interest expense and other   (202,463)  (99,304)  (103,159) 103.9%
     Net loss  $(1,928,128) $(3,295,428)  1,367,300  -41.5%

12


Revenue

During fiscal 2012, revenue consisted primarily of partial payments of $161,951 on sales ofNano Reactor® Systemto four international clients as well as service fees of $23,828. During the year ended June 30, 2011, revenue of $589,926 was derived largely from the sale of twoNANO Neutralization System s to domestic clients in the vegetable oil refining line of business.

Operating Expenses

Operating expenses for fiscal 2012 amounted to $1,872,317 versus $3,694,906 for fiscal 2011, a decrease of $1,822,589. The decrease was attributable to dramatic drops in G&A and R&D expenses. G&A declined by $1,309,597, or 43% as consulting fees and bonus payments declined by $1,687,140. R&D dropped $512,992 as we tended to rely more on our partner, Desmet Ballestra, for R&D. The major components of G&A during fiscal 2012 were $1,005,491 in compensation and associated taxes and $172,881 in professional services including audit and accounting. In fiscal 2011, compensation amounted to $341,322 and professional service fees were $376,758.

Interest Expense and Other

Interest expense and other consists of interest expense and change in value of derivatives. Interest expense for the year ended June 30, 2012 increased by $103,159 compared to 2011. The increase was attributable largely to $133,183 in non-cash expenses associated with convertible notes and derivative liabilities. Only $69,280 was paid in cash consisting of $32,382 in interest expense relating to the bank loan with most of the remaining balance paid in the form of premiums for the pre-payment of convertible promissory notes. Interest expense in fiscal 2011 consisted largely of $39,973 for the bank loan, $34,724 for the amortization of discounts on the issuance of convertible notes payable as well as $19,197 associated with the change in the value of derivatives. 

During fiscal 2012, we issued convertible notes payable amounting to a gross face value of $132,500.  By virtue of the variable conversion ratios contained in the provisions of the agreements, the conversion features of the notes are a derivative under ASC 815-40,Derivatives and Hedging.  Accordingly, the value of the beneficial conversion feature has been classified as a derivative liability on the accompanying balance sheet.  On a quarterly basis, the value of the beneficial conversion feature is adjusted and reflected in derivative liability on the balance sheet. As of June 30, 2012, the aggregate value of the Derivative Liability associated with the above notes amounted to $6,271.  The initial aggregate Derivative Liability value upon the issuance dates amounted to $45,695.  The decrease of $39,424 is recorded in Interest Expense and Other for the year ended June 30, 2012.  

During the year ended June 30, 2011, we issued convertible notes payable amounting to a gross face value of $151,212.  By virtue of the variable conversion ratios contained in the provisions of the agreements, the conversion features of the notes are a derivative under ASC 815-40,Derivatives and Hedging.  Accordingly, the value of the beneficial conversion feature has been classified as a derivative liability on the accompanying balance sheet.  On a quarterly basis, the value of the beneficial conversion feature is adjusted and reflected in derivative liability on the balance sheet. As of June 30, 2011, the aggregate value of the Derivative Liability associated with the above notes amounted to $121,679.  The initial aggregate Derivative Liability value upon the issuance dates amounted to $102,482.  The increase of $19,197 is recorded in Interest Expense and Other for the year ended June 30, 2011.  There was no such expense in 2010.

Liquidity and Capital Resources

For fiscal 2012 gross financing of $543,771 less $136,834 in payments on the bank loan resulted in net financing of $406,937. Funding included short term loans of $214,521 which are expected to be invested in convertible promissory notes to be issued by the company. We also received $125,000 in advances against future sales from our partner, Desmet Ballestra. We sold $35,000 in common stock and received net proceeds of $85,000 from convertible notes. Net short term loans from affiliates increased by $84,250.

13


Our ability to continue to access these sources of financing can be impacted by many factors. See Note 7, "Convertible Notes Payable," Note 8 "Related Party Short-Term Loans," Note 9, "Short-Term Loans," and Note 10, "Stockholder's Equity" for more information.

Sources and Uses of Cash

During fiscal 2012, net use of cash in operating activities amounted to $230,895, a 62% reduction over fiscal 2011.

This cash was used largely to pay fixed operating costs, professional service providers such as auditors and accountants, and interest expense on the bank loans and convertible debt. Management salary was accrued.

Net cash used in investing activities during fiscal 2012 amounted to $53,574 including $22,552 for property, plant, and equipment and $31,022 for expenses related to patent filings and $123,366 in fiscal 2011 including $81,038 for property and equipment and $42,328 for patent filing costs.

Fiscal 2012 net cash provided by financing activities of $406,939 included short term loans of $214,521, advances against sales of $125,000, related party payables/loan of $84,250, sale of common stock of $35,000, and $85,000 in net proceeds from the issuance of convertible notes ($132,500 in new borrowings less repayment of $47,500). The Company repaid $136,834 on the bank loan.

Fiscal 2011 net cash provided by financing activities of $752,063 included proceeds from the sale of common stock of $572,741, convertible notes payable of $151,212, and short-term loans of $90,750. These proceeds were offset by $38,640 in payments on our bank loan as well as a repayment of $24,000 for short term loans.

Off-balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

ITEM 7A.  Quantitative and Qualitative Disclosures about Market Risk.

Not applicable for Smaller Reporting Companies.

14


ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Cavitation Technologies, Inc.

We have audited the accompanying consolidated balance sheets of Cavitation Technologies, Inc. (a development stage company) as of June 30, 2012 and 2011, and the related consolidated statements of operations, changes in stockholders' deficit, and cash flows for the years ended June 30, 2012 and 2011, and the period from January 29, 2007 (inception date) through June 30, 2012. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Cavitation Technologies, Inc. as of June 30, 2012 and 2011, and the results of its operations and its cash flows for the years ended June 30, 2012 and 2011 and the period from January 29, 2007 (inception date) through June 30, 2012, in conformity with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has incurred losses in developing its business and further losses are anticipated. The Company requires additional funds to meet its obligations and the costs of operations. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in this regard are described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Rose, Snyder & Jacobs

Rose, Snyder & Jacobs, LLP

Encino, California
October 9, 2012

15


CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
Consolidated Balance Sheets

   June 30,  June 30,
   2012  2011
ASSETS
       
Current assets:      
     Cash and cash equivalents $137,249  $14,779 
     Inventory  141,057   92,475 
     Prepaid expenses and other current assets    3,337 
     Related party advances  23,853   
          Total current assets  302,159   110,591 
       
Property and equipment, net   135,615   159,344 
Patents, net  123,158   118,153 
Other assets  9,500   9,500 
          Total assets $570,432  $397,588 
       
LIABILITIES AND STOCKHOLDERS' DEFICIT      
       
Current liabilities:      
     Accounts payable  $187,095  $143,949 
     Accrued expenses  126,767   54,745 
     Accrued payroll  992,806   149,316 
     Advances from customers  136,533   36,533 
     Deferred revenue  147,444   16,951 
     Convertible notes payable, net of discounts  29,083   52,852 
     Derivative liability  6,271   121,679 
     Related party payable  59,608   15,750 
     Short-term loan  274,521   60,000 
     Bank loan  349,276   486,110 
     Short-term loan, related parties  100,000   
     Advances from partner  125,000   
          Total current liabilities  2,534,404   1,137,885 
       
Commitments and contingencies, Note 11      
       
Stockholders' deficit:      
     Preferred stock, $0.001 par value, 10,000,000 shares
     authorized, 0 and 111,111 shares issued and
     outstanding as of June 30, 2012 and June 30, 2011,
     respectively.
    111 
     Common stock, $0.001 par value, 1,000,000,000
     shares authorized, 163,969,569 shares and
     153,799,715 shares are issued and outstanding as of
     June 30, 2012 and June 30, 2011, respectively
  165,971   153,800 
     Additional paid-in capital  16,650,959   15,954,280 
     Deficit accumulated during the development stage  (18,780,902)  (16,848,488)
          Total stockholders' deficit  (1,963,972)  (740,297)
          Total liabilities and stockholders' deficit $570,432  $397,588 

See accompanying notes, which are an integral part of these financial statements

16


CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
Consolidated Statements of Operations

          January 29, 2007,
          Inception,
    For the Years Ended  Through
    June 30,  June 30,
    2012  2011  2012
Revenue  $187,216  $589,926  $777,142 
Cost of revenue   40,564   91,144   131,708 
     Gross profit   146,652   498,782   645,434 
General and administrative expenses   1,720,315   3,029,912   13,012,597 
Research and development expenses   152,002   664,994   5,440,396 
Total operating expenses   1,872,317   3,694,906   18,452,993 
     Loss from operations   (1,725,665)  (3,196,124)  (17,807,559)
Interest expense and other   (202,463)  (99,304)  (790,232)
     Net loss before income taxes   (1,928,128)  (3,295,428)  (18,597,791)
Income tax expense   -    -    -  
     Net loss   (1,928,128)  (3,295,428)  (18,597,791)
Deemed dividends to preferred stockholders   (4,286)  (6,000)  (183,111)
     Net loss available to common stockholders  $(1,932,414) $(3,301,428) $(18,780,902)
           
Net loss available to common shareholders per share:          
Basic and Diluted  $(0.01) $(0.02)   
           
Weighted average shares outstanding:          
Basic and Diluted   159,195,686   139,150,615    

See accompanying notes, which are an integral part of these financial statements

17


CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
Consolidated Statements of Changes in Stockholders' Deficit

                 Deficit   
                 Accumulated   
                 During the   
  Series A Preferred  Common Stock  Additional Paid-in  Development   
  Shares  Amount  Shares  Amount  Capital  Stage  Total
                     
Balance at inception, January 29, 2007  -   -    -   -   -   -   -  
                     
Common stock issued as payment for services on January 29, 2007        42,993,630   42,994   (21,994)     21,000 
Common stock issued as payment for services on March 31, 2008        6,428,904   6,429   1,123,971      1,130,400 
Common stock issued as payment for services on April 16, 2008        51,180   51   8,949      9,000 
Common stock issued as payment for services on April 22, 2008        102,360   102   17,898      18,000 
Common stock issued as payment for services on June 18, 2008        3,787,320   3,788   662,212      666,000 
Common stock sold for cash on June 30, 2008        2,047,200   2,047   497,953      500,000 
Amortization of discount on convertible preferred stock              47,879   (47,879)  -  
Net loss                  (2,681,782)  (2,681,782)
                     
Balance at June 30, 2008  -    -    55,410,594   55,411   2,336,868   (2,729,661)  (337,382)
                     
Common stock sold in connection with reverse merger for cash on October 3, 2008        2,149,560   2,150   122,850      125,000 
Preferred stock sold for cash on March 17, 2009  111,111   111         99,889      100,000 
Preferred stock - beneficial conversion feature              11,111   (11,111)  -  
Common stock sold for cash on April 22, 2009        499,998   500   99,500      100,000 
Common stock sold for cash on June 4, 2009        499,998   500   99,500      100,000 
Common stock sold for cash on June 22, 2009        300,000   300   49,700      50,000 
Common stock sold for cash on June 30, 2009        300,000   300   49,700      50,000 
Bio common stock outstanding before reverse merger on October 3, 2008        27,840,534   27,840   (27,840)     -  
Common stock issued as payment for services on September 22, 2008        150,000   150   17,850      18,000 
Common stock issued as payment for services on December 3, 2008        450,000   450   187,150      187,600 
Common stock issued as payment for services on December 17, 2008        300,000   300   131,800      132,100 
Common stock issued as payment for services on February 27, 2009        590,565   591   156,893      157,484 
Common stock issued as payment for services on March 11, 2009        86,550   86   26,853      26,939 
Common stock issued as payment for services on March 22, 2009        150,000   150   50,350      50,500 
Common stock issued as payment for services on April 23, 2009        29,415   29   9,285      9,314 
Common stock issued as payment for services on May 28, 2009        152,379   152   38,959      39,111 
Common stock issued as payment for services on June 4, 2009        37,500   38   9,837      9,875 
Common stock issued as payment for services on June 30, 2009        37,500   38   8,712      8,750 
Warrants issued with convertible debt in December 2008, January 2009 and February 2009              49,245      49,245 
Amortization of discount on convertible preferred stock              107,835   (107,835)  -  
Warrants issued as payment for services on May 27, 2009              56,146      56,146 
Warrants issued as payment for services on June 3, 2009              84,219      84,219 
Warrants issued as payment for services on June 30, 2009              5,678      5,678 
Issuance of stock options as payment for services on August 8, 2008              229,493      229,493 
Issuance of stock options as payment for services on October 1, 2008              4,598      4,598 
Issuance of stock options as payment for services on October 7, 2008              22,770      22,770 
Issuance of stock options as payment for services on October 21, 2008              47      47 
Issuance of stock options as payment for services on October 28, 2008              33      33 
Issuance of stock options as payment for services on January 19, 2009              50,571      50,571 
Net loss                 (2,495,991)  (2,495,991)
                     
Balance at June 30, 2009  111,111  111   88,984,593  88,985  4,089,602  (5,344,598) (1,165,900)

18


CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
Consolidated Statements of Changes in Stockholders' Deficit (Continued)

                 Deficit   
                 Accumulated   
                 During the   
  Series A Preferred  Common Stock  Additional Paid-in  Development   
  Shares  Amount  Shares  Amount  Capital  Stage  Total
                     
Balance at June 30, 2009  111,111  111   88,984,593  88,985  4,089,602  (5,344,598) (1,165,900)
                     
Common stock issued as payment for services on July 27, 2009        17,358,000   17,358   3,886,279      3,903,637 
Common stock issued as payment for services on August 5, 2009        165,000   165   44,935      45,100 
Common stock issued as payment for services on September 16, 2009        190,011   190   42,209      42,399 
Common stock issued as payment for services on October 7, 2009        130,500   131   42,500      42,631 
Common stock issued as payment for services on October 16, 2009        100,911   101   34,209      34,310 
Common stock issued as payment for services on October 23, 2009        30,000   30   9,270      9,300 
Common stock issued as payment for services on October 29, 2009        37,500   38   13,463      13,501 
Common stock issued as payment for services on November 3, 2009        37,500   37   13,464      13,501 
Common stock issued as payment for services on November 10, 2009        35,102   35   12,251      12,286 
Common stock issued as payment for services on November 16, 2009        1,505,000   1,505   405,944      407,449 
Common stock issued as payment for services on November 30, 2009        60,000   60   17,340      17,400 
Common stock issued as payment for services on December 4, 2009        49,157   49   12,240      12,289 
Common stock issued as payment for services on January 11, 2010        121,286   121   30,200      30,321 
Common stock issued as payment for services on February 1, 2010        5,125,102   5,125   1,071,146      1,076,271 
Common stock issued as payment for services on February 11, 2010        500,000   500   109,500      110,000 
Common stock issued as payment for services on February 15, 2010        127,500   128   26,648      26,776 
Common stock issued as payment for services on February 23, 2010        135,000   135   26,865      27,000 
Common stock issued as payment for services on March 5, 2010        346,098   346   82,897      83,243 
Common stock issued as payment for services on March 12, 2010        70,000   70   13,455      13,525 
Common stock issued as payment for services on March 22, 2010        50,000   50   8,450      8,500 
Common stock issued as payment for services on April 12, 2010        127,282   127   16,420      16,547 
Common stock issued as payment for services on April 19, 2010        100,000   100   16,900      17,000 
Common stock issued as payment for services on April 29, 2010        1,700,000   1,700   253,300      255,000 
Common stock issued as payment for services on May 10, 2010        773,750   774   115,288      116,062 
Common stock issued as payment for services on May 24, 2010        219,092   219   43,599      43,818 
Common stock issued as payment for services on June 1, 2010        163,794   164   29,319      29,483 
Common stock issued as payment for services on June 9, 2010        333,333   333   59,667      60,000 
Common stock issued as payment for services on June 14, 2010        46,544   47   8,331      8,378 
Common stock issued for debt and accrued interest conversion on August 7, 2009        1,122,375   1,122   189,681      190,803 
Conversion feature on convertible notes payable              63,601      63,601 
Common stock sold for cash on October 13, 2009        208,104   208   34,156      34,364 
Common stock sold for cash on October 16, 2009        2,980,734   2,981   493,808      496,789 
Common stock sold for cash on November 4, 2009        217,117   217   36,183      36,400 
Common stock sold for cash on November 17, 2009        421,529   422   71,748      72,170 
Common stock sold for cash on December 4, 2009        352,451   352   59,565      59,917 
Common stock sold for cash on January 6, 2010        58,058   58   9,812      9,870 
Common stock sold for cash on February 4, 2010        888,235   888   150,112      151,000 
Common stock sold for cash on March 2, 2010        743,746   744   125,693      126,437 
Common stock sold for cash on March 12, 2010        352,941   353   59,647      60,000 
Common stock sold for cash on April 19, 2010        125,000   125   14,875      15,000 
Common stock sold for cash on June 1, 2010         700,000   700   69,300      70,000 
Common stock issued for conversion of note payable on June 1, 2010        2,789,217   2,789   276,133      278,922 
Common stock sold for cash on June 24, 2010         1,000,000   1,000   99,000      100,000 
Warrants issued as payment for services on July 15, 2009              13,205      13,205 
Warrants issued as payment for services on February 11, 2010              131,376      131,376 
Conversion feature of note payable on June 1, 2010              223,137      223,137 
Dividends on preferred stock                 (6,000)  (6,000)
Net loss                 (8,196,462)  (8,196,462)
                     
Balance at June 30, 2010  111,111  111   130,581,562  130,582  12,656,723  (13,547,060) (759,644)

See accompanying notes, which are an integral part of these financial statements

19


CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
Consolidated Statements of Changes in Stockholders' Deficit (Continued)

                 Deficit   
                 Accumulated   
                 During the   
  Series A Preferred  Common Stock  Additional Paid-in  Development   
  Shares  Amount  Shares  Amount  Capital  Stage  Total
                     
Balance at June 30, 2010  111,111  111   130,581,562  130,582  12,656,723  (13,547,060) (759,644)
                     
Common stock issued as payment for services on July 8, 2010        349,571   350   52,086      52,436 
Common stock issued as payment for services on August 3, 2010        1,854,009   1,854   350,406      352,260 
Common stock issued as payment for services on August 30, 2010        75,000   75   11,175      11,250 
Common stock issued as payment for services on September 8, 2010        237,192   237   35,342      35,579 
Common stock issued as payment for services on October 1, 2010        473,517   474   70,554      71,028 
Common stock issued as payment for services on November 1, 2010        1,020,482   1,020   131,643      132,663 
Common stock issued as payment for services on November 22, 2010        100,000   100   11,900      12,000 
Common stock issued as payment for services on December 7, 2010        459,056   459   50,037      50,496 
Common stock issued as payment for services on January 10, 2011        116,916   117   13,913      14,030 
Common stock issued as payment for services on February 14, 2011        1,264,883   1,265   137,872      139,137 
Common stock issued as payment for services on March 10, 2011        219,767   220   21,757      21,977 
Common stock issued as payment for services on March 22, 2011        510,000   510   50,490      51,000 
Common stock issued as payment for services on April 1, 2011        816,145   816   80,799      81,615 
Common stock issued as payment for services on May 17, 2011        276,203   276   27,343      27,619 
Common stock issued as payment for services on June 13, 2011        333,924   334   33,058      33,392 
Common stock issued as payment for services on June 14, 2011        8,096,990   8,097   689,603      697,700 
Common stock sold for cash on August 3, 2010        593,211   593   58,728      59,321 
Common stock sold for cash on October 1, 2010        661,000   661   78,659      79,320 
Common stock sold for cash on November 1, 2010        1,400,000   1,400   142,600      144,000 
Common stock sold for cash on November 22, 2010        350,000   350   41,650      42,000 
Common stock sold for cash on January 10, 2011        110,000   110   11,990      12,100 
Common stock sold for cash on February 14, 2011        1,920,000   1,920   190,080      192,000 
Common stock sold for cash on March 2, 2011        290,000   290   28,710      29,000 
Common stock sold for cash on March 10, 2011        176,923   177   14,823      15,000 
Common stock issued as payment of short-term loan into stock on February 14, 2011        1,000,000   1,000   99,000      100,000 
Warrants issued as payment for services on November 22, 2010              46,735      46,735 
Common stock issued for conversion of note payable on February 8, 2011        30,769   31   1,967      1,998 
Common stock issued for conversion of note payable on February 11, 2011        15,385   15   985      1,000 
Common stock issued for conversion of note payable on February 16, 2011        26,154   26   1,674      1,700 
Common stock issued for conversion of note payable on February 17, 2011        15,385   15   985      1,000 
Common stock issued for conversion of note payable on February 22, 2011        21,927   22   1,475      1,497 
Common stock issued for conversion of note payable on February 28, 2011        55,749   56   3,568      3,624 
Common stock issued for conversion of note payable on March 7, 2011        24,796   25   1,506      1,531 
Common stock issued for conversion of note payable on March 8, 2011        18,100   18   982      1,000 
Common stock issued for conversion of note payable on March 14, 2011        109,783   110   5,956      6,066 
Common stock issued for conversion of note payable on March 28, 2011        51,282   51   2,949      3,000 
Common stock issued for conversion of note payable on March 30, 2011        59,829   60   3,440      3,500 
Common stock issued for conversion of note payable on April 4, 2011        59,829   60   3,440      3,500 
Common stock issued for conversion of note payable on April 5, 2011        24,376   24   1,402      1,426 
Amortization of restricted stock issued for services              786,275      786,275 
Dividends on preferred stock                 (6,000)  (6,000)
Net loss                 (3,295,428)  (3,295,428)
                     
Balance at June 30, 2011  111,111  111   153,799,715  153,800  15,954,280  (16,848,488) (740,297)

20


CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
Consolidated Statements of Changes in Stockholders' Deficit (Continued)

                 Deficit   
                 Accumulated   
                 During the   
  Series A Preferred  Common Stock  Additional Paid-in  Development   
  Shares  Amount  Shares  Amount  Capital  Stage  Total
                     
Balance at June 30, 2011  111,111  111   153,799,715  153,800  15,954,280  (16,848,488) (740,297)
                     
Common stock issued as payment for services on July 13, 2011        379,449   380   25,968      26,348 
Common stock issued as payment for services on August 19, 2011        198,879   199   10,541      10,740 
Common stock issued as payment for services on August 22, 2011        230,000   230   12,191      12,421 
Common stock issued as payment for services on September 29, 2011        366,924   367   13,787      14,154 
Common stock issued for conversion of note payable on August 16, 2011        287,356   287   20,786      21,073 
Common stock issued for conversion of note payable on August 17, 2011        391,850   392   25,949      26,341 
Common stock issued for conversion of note payable on August 19, 2011        391,850   392   25,949      26,341 
Common stock issued for conversion of note payable on August 22, 2011        288,401   288   17,216      17,504 
Common stock issued for conversion of note payable on September 13, 2011        30,769   31   1,508      1,539 
Common stock issued for conversion of note payable on September 15, 2011        46,154   46   2,262      2,308 
Common stock issued for conversion of note payable on September 16 2011        76,923   77   4,538      4,615 
Common stock sold for cash on August 22, 2011        600,000   600   34,400      35,000 
Common stock issued for conversion of note payable on October 4, 2011        130,474   130   4,818      4,948 
Common stock issued for conversion of note payable on October 5, 2011        178,891   179   6,943      7,122 
Common stock issued for conversion of note payable on October 6, 2011        429,338   429   16,663      17,092 
Common stock issued for conversion of note payable on October 10, 2011        35,778   36   1,388      1,424 
Common stock issued for conversion of note payable on October 11, 2011        194,231   194   6,929      7,123 
Common stock issued as payment for services on October 25, 2011        44,000   44   1,653      1,697 
Common stock issued as payment for services on November 1, 2011        353,959  354   13,300      13,654 
Common stock issued as payment for services on November 22, 2011        87,500  88   2,612      2,700 
To record prepayment of convertible promissory note December 6, 2011              24,591     24,591
Common stock issued for conversion of note payable on January 25, 2012        230,769  231  6,692     6,923
Common stock issued for conversion of note payable on January 26, 2012        179,487  179  5,205     5,384
Common stock issued for conversion of note payable on January 27, 2012        102,564  103  4,000     4,103
Common stock issued for conversion of note payable on January 30, 2012        76,923  77  3,000     3,077
Common stock issued for conversion of note payable on January 31, 2012        338,462  338  13,200     13,538
Common stock issued for conversion of note payable on February 1, 2012        153,846  154  6,000     6,154
Common stock issued for conversion of note payable on February 17, 2012        50,441  50  2,063     2,113
Common stock issued for conversion of note payable on February 21, 2012        249,750  250  9,740     9,990
Common stock issued for conversion of note payable on March 5, 2012        82,124  82  2,382     2,464
Common stock issued for conversion of note payable on March 9, 2012        122,587  123  3,555     3,678
Common stock issued for conversion of note payable on March 12, 2012        183,880  184  5,333     5,517
Common stock issued for conversion of note payable on March 13, 2012        91,940  92  2,666     2,758
Common stock issued for conversion of note payable on March 16, 2012        61,538  62  1,785     1,847
Common stock issued for conversion of note payable on March 26, 2012        200,669  201  5,819     6,020
Common stock issued for conversion of note payable on March 27, 2012        66,890  67  1,940     2,007
Common stock issued for conversion of note payable on March 29, 2012        100,334  100  2,910     3,010
Common stock issued for conversion of note payable on March 30, 2012        196,399  196  5,696     5,892
Issuance of stock options as payment for services on February 16, 2012              168,928     168,928
Common stock issued as payment for services on January 5, 2012        140,792  141  5,290     5,431
Common stock issued as payment for services on February 7, 2012        87,500  88  1,937     2,025
Common stock issued as payment for services on February 16, 2012        2,000,000  2,000  44,290     46,290
Conversion of Convertible Preferred Shares to Common Shares on March 18, 2012  (111,111)  (111)  442,570  443  17,687     18,019
Common stock issued for conversion of note payable on April 3, 2012        60,096   60   1,743      1,803
Common stock issued for conversion of note payable on April 17, 2012        60,332   60   1,750      1,810
Common stock issued for conversion of note payable on April 19, 2012        66,365   66   1,925      1,991
Common stock issued for conversion of note payable on April 23, 2012        267,559   268   7,758      8,026
Common stock issued for conversion of note payable on April 23, 2012        113,311   113   3,286      3,399
Common stock issued for conversion of note payable on June 1, 2012            5,136     5,136
Issuance of stock options as payment for services on March 31, 2012            16,570     16,570
Issuance of stock options as payment for services on March 31, 2012            570     570
Issuance of stock options as payment for services on June 30, 2012            34,271     34,271
Issuance of stock options as payment for services on June 30, 2012            1,172     1,172
Common stock issued as payment for services on June 3, 2012        200,000  200  4,429     4,629
Common stock issued for conversion of note payable on June 6, 2012        1,500,000   1,500   23,960      25,460 
Dividends on Preferred Stock                 (4,286)  (4,286)
Net Loss                 (1,928,128)  (1,928,128)
Balance at June 30, 2012  -   $-    165,969,569  $165,971  $16,650,959  $(18,780,902) $(1,963,972)

See accompanying notes, which are an integral part of these financial statements

21


CAVITATION TECHNOLOGIES, INC.
(A Development Stage Company)
Consolidated Statements of Cash Flows

            January 29, 2007,
            inception thru
      Years Ended June 30,  June 30,
      2012  2011  2012
             
Operating activities:            
Net loss    $(1,928,128) $(3,295,428) $(18,597,791)
Adjustments to reconcile net loss to net cash             
     used in operating activities:            
     Depreciation and amortization     50,540   21,123   101,250 
     Warrants issued in connection with convertible notes payable         49,245 
     Beneficial conversion feature on convertible notes payable     108,987   34,724   430,449 
     Common stock issued for services     135,459   2,570,457   11,666,060 
     Stock option compensation     221,511     529,023 
     Warrants issued for services       46,735   337,359 
     Change in value of derivatives     (19,007)  19,197   190 
     Equipment write-down       5,399   5,399 
     Patent write-down     21,758   13,500   35,259 
             
Effect of changes in:            
     Inventory     (48,581)  (53,056)  (101,637)
     Prepaid expenses and other current assets     (20,516)  (179)  (20,516)
     Bank overdraft       (2,747)  (9,500)
     Accounts payable and accrued expenses     129,242   (42,900)  326,634 
     Accrued payroll     843,490   66,264   1,252,456 
     Advances - Related Party Payables     43,858   19,271   59,792 
     Advances from customers     100,000     136,533 
     Deferred revenue     130,494   (16,548)  147,444 
          Net cash used in operating activities     (230,893)  (614,188)  (3,652,351)
             
Investing activities:            
     Purchase of property and equipment     (22,552)  (81,038)  (121,744)
     Payments for systems         (152,721)
     Payments for patents     (31,022)  (42,328)  (165,634)
          Net cash used in investing activities     (53,574)  (123,366)  (440,099)
             
Financing activities:            
     Proceeds from (payments on) bank loan borrowings     (136,834)  (38,640)  349,276 
     Proceeds from sales of preferred stock       -    725,000 
     Proceeds from convertible notes payable     85,000   151,212   471,212 
     Payments on convertible notes payable       -    (55,000)
     Proceeds from sale of common stock     35,000   572,741   2,139,690 
     Proceeds from related party short-term loans     84,250   15,750   100,000 
     Proceeds from short-term loans     214,521   75,000   398,521 
     Payments on short-term loans       (24,000)  (24,000)
     Advances against sales     125,000     125,000 
          Net cash provided by financing activities     406,937   752,063   4,229,699 
             
             
Net increase (decrease) in cash     122,470   14,509   137,249 
Cash, beginning of period     14,779   270   
Cash, end of period    $137,249  $14,779  $137,249 
             
Supplemental disclosures of cash flow information:            
     Cash paid for interest    $69,280  $42,610  $262,872 
     Cash paid for income taxes    $1,600  $1,600  $8,328 
Supplemental disclosure of non-cash investing and financing activities:            
     Warrants issued in connection with preferred stock    $ $ $155,714 
     Beneficial conversion feature on preferred stock    $ $ $11,111 
     Conversion of preferred to common shares in reverse merger    $ $ $625,000 
     Proceeds from sales of preferred shares used to purchase shares of Bio    $ $ $400,000 
     Conversion of note payable to common stock    $ $ $278,922 
     Conversion of related party short-term loan to common stock    $ $100,000  $100,000 
     Accrued dividends issued to preferred stockholders    $ $6,000  $13,733 
     Conversion of convertible notes payable and accrued interest to common stock    $152,127  $30,843  $373,773 

See accompanying notes, which are an integral part of these financial statements

22


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1 - Organization

Hydrodynamic Technology, Inc. was incorporated January 29, 2007 as a California corporation. It is a wholly owned subsidiary of Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as "the Company," "CTi," "we," "us," and "our") a Nevada corporation originally incorporated under the name Bio Energy, Inc. CTi has developed, patented, and commercialized proprietary technology that may be used in liquid processing applications. CTi's patentedNano Reactor® is the critical component of CTiNano Neutralization® System which is commercially proven to reduce operating costs and increase yields in refining vegetable oils. CTi has two patented systems and has filed several national and international patents to employ its proprietary technology in applications including, vegetable oil refining, waste water treatment, algae oil extraction, and alcoholic beverage enhancement.

Note 2 - Basis of Presentation and Going Concern

Management's Plan Regarding Going Concern

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company as a going concern.  The Company has not generated significant revenue and, from January 29, 2007, (inception), through June 30, 2012, generated a net loss of $18,597,791. The Company also has negative cash flow from operations and negative net equity.  These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern.

Management's plan is to generate income from operations by licensing our technology globally through our strategic partner, the Desmet Ballestra Group. Desmet has agreed to provide us limited monthly advances against future sales. As of June 30 and August 30, 2012, advances received amounted to $125,000 and $375,000 respectively. Minimum monthly advances from Desmet amount to $125,000. In addition, in the first quarter of fiscal 2013, the Company signed an agreement with the GEA Westfalia Separator Group. The purpose of the agreement is to jointly develop and patent new process applications for CTi's technology.

We will also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company's needs, or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

The accompanying consolidated financial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from an inability of the Company to continue as a going concern.

Basis of Presentation

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles ("GAAP") as promulgated in the United States of America ("U.S.").

Note 3 - Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. All significant inter-company transactions and balances have been eliminated through consolidation.

23


Fair Value Measurement

FASB Accounting Standards Codification ("ASC") 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of June 30, 2012 and 2011, the carrying value of certain accounts such as inventory, accounts payable, accrued expenses, accrued payroll and short-term loans approximate fair value due to the short-term nature of such instruments.    

The following table presents information about the Company's assets and liabilities measured and reported in the financial statements at fair value on a recurring basis as of June 30, 2012 and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value. The three levels of the fair value hierarchy are as follows:

   Fair Value  Fair Value Measurements at June 30, 2012
   as of  Using Fair Value Heirarchy
Financial Instruments  June 30, 2012  Level 1  Level 2  Level 3
             
Liabilities:            
     Derivative liability  6,271   -    -    6,271 
Total $6,271  $-   $-   $6,271 

The following tables provide a reconciliation of the beginning and ending balances of our financial liabilities classified as Level 3:

Fair Value Measurements Using Significant
Unobservable Inputs (Level 3)
Derivative Liability
Balance at June 30, 2011$121,679 
Total (gains) losses included in interest expense and other(19,007)
Creation - convertible note issuances45,696 
Settlements - note conversions(142,097)
Balance at June 30, 2012$6,271 

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in valuing our stock options, warrants, convertible notes, and common stock issued for services, among other items. Actual results could differ from these estimates.

24


Revenue Recognition

Revenue from the sale of ourNano Reactor® Systems is recognized when persuasive evidence of an agreement exists; delivery has occurred, including transfer of title and risk of loss for product sales, or services have been rendered for service revenues; the price to the buyer is fixed or determinable; and collectability is reasonably assured. The Company employs the Milestone Method of Revenue Recognition. Accounting Standard Codification 605-28-15 describes the Milestone Method as pertaining to R&D deliverables under which the Company satisfies its performance obligations over a period of time and which a portion or all of the consideration is contingent upon uncertain future events or circumstances. For agreements that provide for milestone payments such as our agreement with Desmet Ballestra, we adopted ASC 605-28-25, "Revenue Recognition Milestone Method." The Company used this method of accounting to record revenue associated with the Desmet transactions.

Deferred Revenue and Advances from Customers

As of June 30, 2012, the Company had received total deposits of $147,444 relating to license fees associated with two of the Company'sNANO Neutralization Systems. Once the systems show that they meet performance specifications and have been acknowledged by the client, then the revenue will be recognized. Until then, this amount has been reflected in Deferred Revenue on the accompanying consolidated balance sheet as of June 30, 2012.

In addition, we received an advance of $100,000 from a client for a license fee. Once the system has been installed, meets performance specifications, and is accepted by the client, we will recognize revenue.

Cash

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents are carried at cost which approximates market value.  The Company maintains cash and cash equivalents in bank deposit accounts which, at times, may exceed federally insured limits.  The Company has never experienced losses in such accounts and believes it is not exposed to significant credit risk on cash and cash equivalents.

Inventory

Inventory, net of an allowance for excess quantities and obsolescence, is stated at the lower of cost or market. Cost is determined on a specific item basis. Inventory is composed of finished goods and represents costs incurred to manufacture ourNano Reactor®systems

Property and Equipment

Property and equipment is presented at cost less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the assets. Betterments, renewals, and extraordinary repairs that extend the life of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation applicable to retired assets are removed from the Company's accounts, and the gain or loss on dispositions, if any, is recognized in the consolidated statements of operations.

Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives.

Leasehold improvements

Shorter of life of asset or lease

Furniture

5-7 Years

Office equipment

5-7 Years

Lab equipment

4-7 Years

Skid systems (demo units)

4 Years

25


Patents

Capitalized patent costs represent legal fees associated with procuring and filing patent applications. The Company accounts for patents in accordance with ASC 350-30,General Intangibles Other Than Goodwill. As of June 30, 2012, the Company had incurred $129,334 in gross patent costs which are capitalized in the accompanying consolidated balance sheet. The Company had one patent issued during fiscal 2012 and one issued in fiscal 2011 both of which are being amortized over an estimated useful life of 4 years. We believe that four years is a reasonable estimate based upon our estimate of time until the next generation of reactors is developed or until other forms of competition appear. The patents have a duration of twenty years from filing date. For the years ended June 30, 2012 and June 30, 2011 amortization amounted to $4,258 and $1,918 respectively. At June 30, 2012, future estimated patent amortization costs are:

2013 $7,964 
2014  11,760 
2015  15,936 
2016  20,530 
2017  25,583 
Thereafter  41,385 
Total $123,158 

Impairment of Intangible and Long-Lived Assets

In accordance with ASC 350-30 (General Intangibles Other than Goodwill), the Company evaluates amortizable intangibles and long-lived assets for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amount. Impairment, if any, is based on the excess of the carrying amount over the fair value, based on market value when available, or discounted expected cash flows, of those assets and is recorded in the period in which the determination is made. The Company's management believes there is no impairment of its intangibles and long-lived assets. There can be no assurance, however, that market conditions will not change or demand for the Company's products under development will continue. Either of these could result in future impairment of intangibles and long-lived assets.

Share-Based Compensation

The Company accounts for its share-based compensation in accordance ASC 718-20,Share-Based Payment.  Stock-based compensation cost is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense over the requisite vesting period.  During fiscal 2012, 11,750,000 stock options were granted and valued at $320,488 with $221,511 recognized in fiscal 2012 and included in theStatement of Operations. Remaining expenses will be recognized over the vesting periods in accordance with the assumptions cited below. There were no stock options granted during fiscal 2011. The table below represents the assumptions for valuing the warrants granted in fiscal 2011 and stock options granted in fiscal 2012.

26


  Year Ended June 30,
  2012 2011
Expected life in years  5-6.5 3.0
Stock price volatility  147.0% 132.1%
Risk free interest rate  0.86% 0.72%
Expected dividends None  None 
Forfeiture rate 0% 0%

The assumptions used in the Black Scholes models referred to above are based upon the following data: (1) The contractual life of the underlying non-employee warrants is the expected life; The expected life of the option is estimated by considering the contractual term of the option, the vesting period of the option, the employees' expected exercise behavior and the post-vesting employee turnover rate. (2) The expected stock price volatility of the underlying shares over the expected term of the option or warrant is based upon historical share price data of the Company. (3) The risk free interest rate is based on published U.S. Treasury Department interest rates for the expected terms of the underlying options. (4) Expected dividends are based on historical dividend data and expected future dividend activity. (5) The expected forfeiture rate is based on historical forfeiture activity and assumptions regarding future forfeitures based on the composition of current grantees.

Income Taxes

The Company accounts for income taxes in accordance with ASC 740-10,Income Taxes.  The Company recognizes deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at anticipated future tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. The Company classifies interest and penalties as a component of interest and other expenses. To date, there have been no interest or penalties assessed or paid.

The Company measures and records uncertain tax positions by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.

Advertising costs

Advertising costs (including marketing expense) incurred in the normal course of operations are expensed as incurred. Advertising expenses amounted to $34,114, $97,135, and $270,552 for the years ended June 30, 2012, and June 30, 2011 and for the period from January 29, 2007 (date of inception) through June 30, 2012, respectively.

Research and Development Costs

Research and development expenses relate primarily to the development, design, testing of preproduction prototypes and models, compensation, and consulting fees, and are expensed as incurred.

27


Recent Accounting Pronouncements

Accounting standards promulgated by the FASB change periodically.  Changes in such standards may have an impact on the Company's future financial position. The following are a summary of recent relevant accounting developments.

In November 2011, the Financial Accounting Standard Board ("FASB") issued ASU 2011-11, "Balance Sheet (topic 210): Disclosures about Offsetting Assets and Liabilities". ASU 2011-11 stipulates that entities are required to disclose both gross information and net information about both instruments and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting arrangement. ASU 2011-11 enhances disclosure required by US GAAP by requiring improved information about financial instruments and derivative instruments. This information will enable users of an entity's financial statements to evaluate the effect or potential effect of netting arrangements on an entity's financial position. This scope would include derivatives, sale and repurchase agreements and reverse sale and repurchase agreements, and securities borrowing and securities lending arrangements An entity is required to apply the amendments for annual reporting periods beginning on or after January 1, 2013 and interim periods within those annual periods. An entity should provide the disclosures required by those amendments retrospectively for all comparative periods presented.

The Company does not expect the adoption of ASU 2011-14 to have a material effect on its operating results or financial position.

In May 2011, the Financial Accounting Standard Board ("FASB") issued ASU 2011-04, Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs. ASU 2011- 04 clarifies some existing concepts, eliminates wording differences between U.S. GAAP and International Financial Reporting Standards ("IFRS"), and in some limited cases, changes some principles to achieve convergence between U.S. GAAP and IFRS. ASU 2011-04 results in a consistent definition of fair value and common requirements for measurement of and disclosure about fair value between U.S. GAAP and IFRS. ASU 2011-04 also expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. ASU 2011-04 will be effective for Cavitation beginning after December 15, 2011. Cavitation does not expect the adoption of ASU 2011-04 to have a material effect on its operating results or financial position.

Dependence on Desmet

Our revenue is almost entirely dependent on Desmet Ballestra who is our exclusive distribution agent with regard to theCTi Nano Neutralization® System. During fiscal 2012, 77% of revenue derived from Desmet sales efforts.

Note 4 -Net Loss per Share - Basic and Diluted

The Company computes the loss per common share using ASC 260,Earnings per Share.  The net loss per common share, both basic and diluted, is computed based on the weighted average number of shares outstanding for the period.  The diluted loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average shares outstanding assuming all potential dilutive common shares were issued.

As of June 30, 2012, the Company had 13,560,957 stock options and 11,222,287 warrants outstanding to purchase common stock that were not included in the diluted net loss per common share because their effect would be anti-dilutive.  The Company also had $33,550 of outstanding convertible notes payable, before discounts, which are convertible into approximately 1,720,513 shares of common stock as of June 30, 2012.  These items were also not included in the calculation of diluted net loss per common share because their effect would be anti-dilutive.

28


Note 5 - Property and Equipment

Property and equipment consisted of the following as of June 30, 2012 and June 30, 2011:

  June 30,  June 30,
  2012  2011
      
Leasehold improvement$2,475  $2,475 
Furniture   26,837   26,837 
Office equipment 1,499   1,500 
Lab equipment 68,380   68,380 
Skid systems 135,027   112,474 
  234,218   211,666 
Less: accumulated depreciation and amortization (98,603)  (52,322)
      
Propert and equipment, net$135,615  $159,344 

Depreciation expense for the years ended June 30, 2012 and 2011 and for the period from January 29, 2007 (inception) through June 30, 2012, amounted to $46,282, $18,164, and $94,033 respectively.

Note 6 -Bank Loan

On August 1, 2010 the Company renewed its loan with National Bank of California until November 1, 2010.  The amount outstanding was $520,516.  The terms and conditions remained the same with monthly payments of $7,396 and an interest rate of prime plus 2.75%.  On November 1, 2010, the loan was extended until November 1, 2011 with 11 regular monthly payment of $6,000 and a final payment of $474,171.  The interest rate floor was increased from 7.0% to 7.5%. On November 1, 2011, the maturity of the variable rate loan was extended to February 1, 2013. Monthly payments include 14 principal payments of $6,000 plus interest. In addition, CTi is to make a quarterly principal payment of $50,000. The remaining principal and accrued interest of approximately $110,000 is due February 1, 2013. As of June 30, 2012, the outstanding balance on the loan was $349,276. The Company provided the National Bank of California a security interest in the assets of the Company as collateral for the loan. In addition, the personal assets of our two founders were pledged as collateral.

Note 7 - Convertible Notes

On February 1, 2011, the Company issued convertible promissory notes to the Tripod Group, LLC, (the "Tripod Notes") for an aggregate total amount of $61,212. The Tripod Notes bore interest at a rate of 6% per annum and have a maturity date of February 1, 2012.  The holder of the notes could elect to convert the outstanding principal and accrued interest into shares of the Company's common stock at a conversion price equal to 65% of the lowest closing bid price of any of the four trading days prior to the conversion.  CTi has the option to pre-pay the note prior to conversion at a premium of 150% of the principal amount. The issuance of the Tripod Notes amounted in a beneficial conversion feature of $32,960 on the issue date, which was recorded as a discount to the carrying value of the notes.  From February through October 2011, Tripod converted the entire $61,212 into 1,635,897 shares of common stock.

29


On February 8, 2011, the Company issued a convertible promissory note payable to Asher Enterprises, Inc., (the "Asher Note"), in the amount of $42,500.  The Asher Note bears interest at a rate of 8% per annum and was to mature on November 10, 2011.  The holder of the note could elect to convert principal and accrued interest into shares of common stock at any time at a conversion price equal to 58% of the average lowest closing bid prices of the Company's common stock for 3 of any 10 trading days prior to conversion. CTi has the option to pre-pay the note prior to conversion at a premium ranging from 130% to 150% of the principal amount. The issuance of the Asher Note amounted in a beneficial conversion feature of $28,412 on the issue date, which was recorded as a discount to the carrying value of the note.  During fiscal 2012, the entire $42,500 was converted into 1,359,457 shares of common stock at a value of $91,258, and the $47,059 beneficial conversion feature was allocated to additional paid in capital.

On June 6, 2011, the Company issued a convertible promissory note payable to Asher Enterprises, Inc., (the "Second Asher Note"), in the amount of $47,500.  The Second Asher Note bore interest at a rate of 8% per annum and matures on March 8, 2012.  The holder of the note could elect to convert principal and accrued interest into shares of common stock at any time at a conversion price equal to 61% of the average lowest closing bid prices of the Company's common stock for 3 of any 10 trading days prior to conversion. CTi has the option to pre-pay the note prior to conversion at a premium ranging from 130% to 150% of the principal amount. The issuance of the Second Asher Note amounted in a beneficial conversion feature of $41,109 on the issue date, which was recorded as a discount to the carrying value of the note.  During the year ended June 30, 2012, the $47,500 outstanding balance was pre-paid incurring a pre-payment penalty (interest expense) of $23,750. The company pre- paid the convertible promissory note as part of our overall strategy to minimize the issuance of shares.

On June 24, 2011, we issued a convertible promissory note payable to GEL Properties, LLC, (the "GEL Note") in the amount of $52,500. The Note is due June 24, 2012 and bore interest at a rate of 6% p.a. The GEL Note was convertible into shares of our common stock at a conversion price equal to 65% of the average day's lowest closing bid out of the 5 trading days prior to conversion. The transaction was funded July 12, 2011. CTi has the option to pre-pay the note prior to conversion at a premium of 150% of the principal amount. The issuance of the GEL Note amounted in a beneficial conversion feature of $28,269 on the issue date which was recorded as a discount to the carrying value of the note. By virtue of the variable conversion ratio, the conversion feature is a derivative under ASC 815-40, Derivatives and Hedging, and accordingly, the value of the conversion feature was classified as a derivative liability on the accompanying balance sheet. During the year ended June 30, 2012, the entire $52,500 in principal plus $2,033 in accrued interest was converted into 3,056,266 shares of common stock at a value of $98,105, and the $45,605 beneficial conversion feature was allocated to additional paid in capital.

On December 6, 2011 we issued a convertible promissory note payable to the Prolific Group, LLC, (the "Prolific Note") in the amount of $25,000. The Note is due December 6, 2012 and bears interest at 6% p.a. The Prolific Note is convertible into shares of our common stock at a conversion price equal to 65% of the average day's lowest closing bid out of the 5 trading days prior to conversion. CTi has the option to pre-pay the note prior to conversion at a premium of 150% of the principal amount. The issuance of the Prolific Note amounted in a beneficial conversion feature of $4,673 on the issue date which has been recorded as a discount to the carrying value of the note. During fiscal 2012, $21,450 was converted to 1,500,000 shares. As of June 30, 2012, the outstanding balance was $3,550 and remaining discount balance amounted to $2,030. By virtue of the variable conversion ratio, the conversion feature is a derivative under ASC 815-40, Derivatives and Hedging, and accordingly, the value of the conversion feature has been classified as a derivative liability on the accompanying balance sheet.

On December 6, 2011 we issued a convertible promissory note payable to the Tripod Group, LLC, (the "Second Tripod Note") in the amount of $30,000. The Note is due December 6, 2012 and bears interest at 6% p.a. The Second Tripod Note is convertible into shares of our common stock at a conversion price equal to 65% of the average day's lowest closing bid out of the 5 trading days prior to conversion. CTi has the option to pre-pay the note prior to conversion at a premium of 150% of the principal amount. The issuance of the Second Tripod Note amounted in a beneficial conversion feature of $5,608 on the issue date which has been recorded as a discount to the carrying value of the note. As of June 30, 2012, the outstanding balance was $30,000 and the remaining discount balance amounted to $2,436. By virtue of the variable conversion ratio, the conversion feature is a derivative under ASC 815-40, Derivatives and Hedging, and accordingly, the value of the conversion feature has been classified as a derivative liability on the accompanying balance sheet. As of June 30, 2012, the outstanding balance was $30,000.

30


On December 21, 2011 we issued a convertible promissory note payable to Asher Enterprises, Inc., (the "Third Asher Note") in the amount of $25,000. The Note is due September 21, 2012 and bears interest at 8% p.a. The Third Asher Note was convertible into shares of our common stock at a conversion price equal to 60% of the average day's lowest trading price during the 10 trading days prior to conversion. CTi has the option to pre-pay the note prior to conversion at a premium ranging from 125% to 150% of the principal amount. The issuance of the Third Asher Note amounted in a beneficial conversion feature of $7,146 on the issue date which was recorded as a discount to the carrying value of the note. During the year ended June 30, 2012, the outstanding balance of $25,000 was pre-paid along with a pre-payment premium of $12,801 which is included as interest expense in the accompanying consolidated financial statements.

On June 30, 2012, the outstanding balance of Convertible Notes Payable (net of discounts) as recorded on the balance sheet amounted to $29,083 consisting of outstanding principal of $33,550 less discount of $4,466. By virtue of the variable conversion ratios of these transactions, the conversion feature of the above notes is a derivative under ASC 815-40,Derivatives and Hedging. Accordingly, the value of the conversion feature has been classified as a derivative liability on the accompanying balance sheet. As of June 30, 2012, the aggregate value of the conversion features associated with the above notes amounted to $6,271.

Note 8 - Related Party Short-Term Loan and Payables

On December 28, 2011, the CEO, Todd Zelek, extended to the company a $100,000 short-term loan due on demand at an annual interest rate of 12%. The outstanding amount at June 30, 2012 was $100,000 and accrued interest amounted to $6,000. On June 30, 2012, the Company had recorded $59,608 in Related Party Payable. These included company related expenses that had been paid by related parties on behalf of the Company. As of September 14, 2012, the outstanding balance had been reduced to less than $10,000.

Note 9 - Short-Term Loans

On October 26, 2010, the Company entered into a loan agreement with Desmet Ballestra North America, Inc. under which the Company borrowed $75,000.  Under the original terms of the agreement, the loan was interest-free and was repayable at $25,000 per month beginning January 25, 2011.  On March 28, 2011, the terms of the loan agreement were revised to provide for monthly payments of $15,000 starting in April 2011. The loan bears no interest unless the Company is late with a payment at which point interest is accrued on the late amount at a rate of 10% compounded annually. Accrued interest on late payments amounted to $5,500 for the year ended June 30, 2012. As of June 30, 2012, the Company had made two payments amounting to $20,000, and the outstanding balance amounted to $55,000.

During fiscal 2012, we received $219,521 from third party lenders and we recorded these funds in Short Term Loans which are due on demand and pay an annual interest rate of 12%. These funds are earmarked for potential conversion into convertible promissory notes to be issued by the Company. One of the interested parties has indicated that he made the deposit specifically for an investment in convertible promissory notes to be issued by the Company. The terms of the deposits are currently being negotiated.

During fiscal 2012 and 2011, CTi had average borrowings of $686,030 and $648,644 respectively under its short-term obligations (bank loan, related party short term loans, convertible notes payable and short-term loans). The weighted average stated interest rate on short-term obligations outstanding as of June 30, 2012 and June 30, 2011 was 9.7% and 6.7% respectively.

31


Note 10 - Stockholders' Equity

Common Stock

During fiscal 2012, the Company issued 3,889,003 shares of common stock valued at $135,459 as payment to service providers including compensation to our CEO. These shares were valued at fair value using discounted market prices. The Company sold 600,000 shares of common stock for proceeds of $35,000, and issued 7,038,281 shares of common stock to convert $147,059 of outstanding principal under the convertible promissory notes (see Note 7). 

During fiscal 2011, the Company issued 16,203,655 shares of common stock as payment for services provided which resulted in an aggregate total expense of $1,784,182, including $1,491,582 in general and administrative expenses and $292,600 in R&D expenses.  The 16,203,655 shares were issued at grant date fair market value. The Company sold 5,501,134 shares of common stock for total proceeds of $572,741. The Company issued 513,364 shares of common stock to convert $30,602 of outstanding principal under the Tripod Notes (see Note 7). On February 14, 2011, the Company issued 1,000,000 shares of common stock as payment of an outstanding short-term loan of $100,000 (see Note 9).

Preferred Stock

On March 17, 2009, the Company  filed Amended and Restated Articles of Incorporation and created two  new series of preferred stock, the first of which is designated Series A Preferred Stock and the second of which is designated as Series B Preferred Stock. The total number of shares of Common Stock which this corporation shall have authority to issue is 100,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock of which 5,000,000 shares are designated as Series A Preferred Stock, and 5,000,000 shares are designated as Series B Preferred Stock, with the rights, preferences and privileges of the Series B Preferred Stock to be designated by the Board of Directors. The company converted 111,111 Series A Preferred Shares plus $18,019 in accrued dividends into 442,570 shares of common stock in March 2012. There are no shares of Series A or Series B Preferred Stock outstanding. Each share of Common Stock and Preferred Stock has a par value of $0.001.

32


Stock Options

The Company has not adopted a formal stock option plan, however, it has assumed outstanding stock options resulting from the acquisition of its wholly-owned subsidiary, Hydrodynamic Technology, Inc. In addition, the Company has made periodic non-plan grants. A summary of the stock option activity from January 29, 2007 (date of inception) through June 30, 2012 follows:

       Weighted-
       Average
     Weighted- Remaining
     Average Contractual
     Exercise Life
  Options  Price (Years)
        
Outstanding at January 29, 2007 (date of inception) -   $-   -  
Granted 2,137,612   0.57   
Exercised -    -    
Outstanding at June 30, 2009 2,137,612   0.57  6.68 
Granted -    -    
Forfeited (150,000)  0.67   
Exercised -    -    
Outstanding at June 30, 2010 1,987,612   0.56  6.16 
Granted -    -    
Forfeited (176,655)  0.67   
Exercised -    -    
Outstanding at June 30, 2011 1,810,957   0.55  5.23 
Granted 11,750,000   0.03  9.88 
Forfeited -    -   -  
Exercised -    -   -  
Expired -    -   -  
Outstanding June 30, 2012 13,560,957   0.10  8.95 
        
Exercisable at June 30, 2012 8,060,957   0.15  8.48 
Vested and expected to vest at June 30, 2012 8,060,957   0.15  8.48 

33


There were 11,750,000 options issued in fiscal 2012. Ten million options were issued to our CEO as compensation with 5,000,000 options exercisable immediately and the other 5,000,000 exercisable February 15, 2013. In addition, 1,250,000 stock options were granted February 16, 2012 to our Director of R&D with 100% of the options exercisable immediately. Also, 500,000 stock options were issued to independent board member and Audit Committee Chairman, Jim Fuller. These options vest over 3 years. The inputs used for the Black-Scholes option valuation model were as follows:

  Year Ended June 30,
  2012 2011
Contract life in years 10.0 N/A
Expected life in years  5-6.5 N/A
Stock price volatility  147.0% N/A
Risk free interest rate  0.86% N/A
Expected dividends None  N/A
Forfeiture rate 0% N/A

There were no stock options granted during fiscal 2011. The intrinsic value of the outstanding options was $0 as of June 30, 2012 and 2011. The following table summarizes additional information concerning options outstanding and exercisable at June 30, 2012.

   Options Outstanding Options Exercisable
     Weighted  Weighted    Weighted
     Average  Average    Average
 Exercise Number Remaining  Exercise Number  Exercise
 Price of Shares Life (Years)  Price of Shares  Price
              
$0.03 11,750,000  9.64  $0.03  6,250,000  $0.03 
 0.33 637,297  4.31   0.33  637,297   0.33 
 0.67 1,173,660  4.59   0.67  1,173,660   0.67 
   13,560,957       8,060,957    

34


Warrants

A summary of the Company's warrant activity and related information from January 29, 2007 (date of inception) through June 30, 2012 is as follows.

       Weighted-
       Average
     Weighted- Remaining
     Average Contractual
     Exercise Life
  Warrants  Price (Years)
        
Outstanding at January 29, 2007 (date of inception) -   $-   -  
Granted 409,440  0.37  
Exercised -    -   -  
Outstanding at June 30, 2008 409,440  0.37 2.75
Granted 4,123,263  0.46  
Exercised -    -    
Outstanding at June 30, 2009 4,532,703  0.45 3.18
Granted 8,012,915  0.40  
Exercised -    -    
Outstanding at June 30, 2010 12,545,618  0.42 2.66
Granted 600,000  0.25  
Exercised -    -    
Outstanding at June 30, 2011 13,145,618  0.41 1.69
Granted -    -   -  
Exercised -    -   -  
Expired 1,923,331   0.36  -  
Outstanding at June 30, 2012 11,222,287   0.42  0.85 
        
Vested at June 30, 2012 11,222,287   0.42  0.85 
        
Exercisable at June 30, 2012 11,222,287   0.42  0.85 

There were no warrants granted in fiscal 2012. The weighted average grant date fair value of warrants granted during fiscal 2011 amounted to $0.08.

The following table summarizes additional information concerning warrants outstanding and exercisable at June 30, 2012.

  Warrants Outstanding Warrants Exercisable
    Weighted  Weighted    Weighted
    Average  Average    Average
Exercise Number Remaining  Exercise Number  Exercise
Price of Shares Life (Years)  Price of Shares  Price
             
0.20 - 0.37 1,939,374  1.37  $0.29  1,939,374  $0.29 
0.42 - 0.58 9,282,913  0.92   0.48  9,282,913   0.48 
  11,222,287       11,222,287    

35


Note 11 - Income Taxes

Total income tax expense differed from the amounts computed by applying the U.S. Federal income tax rate of 34% to income before income tax expense as a result of the following:

       
  

Year Ended

  

Year Ended

 
  

June 30, 2012

  

June 30, 2011

 
       

Computed tax provision at statutory Federal rate

  

34.0

%

  

34.0

%

Increase (decrease) in taxes resulting from:

        

State taxes, net of Federal income tax benefit

  

4.5

%

  

3.2

%

Stock compensation and other permanent differences

  

7.9

%

  

-15.5

%

Change in valuation allowance

  

-46.4

%

  

-21.7

%

         

Effective income tax rate

  

0.0

%

  

0.0

%

Temporary differences between the financial statement carrying amounts and tax bases of assets and liabilities that give rise to significant portions of the net deferred tax asset at June 30, 2012 and June 30, 2011 relate to the following:

  

Year Ended

  

Year Ended

 
  

June 30, 2012

  

June 30, 2011

 
       

Net operating loss

 

$

3,646,000

  

$

2,830,000

 

Stock compensation

  

2,501,000

   

3,290,000

 

Other

  

283,000

   

159,000

 

Valuation allowance

  

(6,430,000

)

  

(6,279,000

)

         

Net deferred tax asset

 

$

-

  

$

-

 

The Company files income tax returns in the United States ("Federal") and California ("State") jurisdictions. The Company is subject to Federal and State income tax examinations by tax authorities for all years since its inception.

At June 30, 2012, the Company had Federal and State net operating loss carry forwards available to offset future taxable income of approximately $8.5 million and $8.5 million, respectively. These carry forwards will begin to expire in the years ending June 30, 2027 and June 30, 2017, respectively, subject to IRS limitations, including change in ownership.

The Company periodically evaluates the likelihood of the realization of deferred tax assets, and adjusts the carrying amount of the deferred tax assets by a valuation allowance to the extent the future realization of the deferred tax assets is not judged to be more likely than not. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors.

At June 30, 2012, based on the weight of available evidence, including cumulative losses in recent years and expectations of future taxable income, the Company determined that it was more likely than not that its deferred tax assets would not be realized. Accordingly, the Company has recorded a valuation allowance for 100% of its cumulative deferred tax assets.

As a result of the implementation of certain provisions of ASC 740-10, the Company performed an analysis of its previous tax filings and determined that there were no positions taken that it considered uncertain. Therefore, there were no unrecognized tax benefits as of June 30, 2012.

36


Future changes in the unrecognized tax benefit are not expected to have an impact on the effective tax rate due to the existence of the valuation allowance. The Company estimates that the unrecognized tax benefit will not change within the next twelve months. The Company will continue to classify income tax penalties and interest, if any, as part of interest and other expenses in its consolidated statements of operations. There is no interest or penalties accrued as of June 30, 2012.

The following summarizes the open tax years for each major jurisdiction:

JurisdictionOpen Tax Years

Federal 2008 - 2011

California 2007- 2011

The Company's net operating loss carryforwards are subject to IRS examination until they are utilized and such tax years are closed.

Note 12 - Commitments and Contingencies

Lease Agreements

The Company leases approximately 5,000 square feet of office and warehouse space at 10019 Canoga Ave in Chatsworth, California under a lease agreement which extends through February 1, 2013. Total rent expense was $59,061, $47,388 and $306,232 for the years ended June 30, 2012, 2011 and for the period from January 29, 2007 (date of inception) through June 30, 2012, respectively. Monthly payments increased to approximately $4,509 beginning February 2012. The Company has a security deposit of $9,500 associated with this lease. Future minimum lease payments under non-cancelable operating leases are:

Year Ended  
June 30,  
   
2013  31,563 
Total $31,563 

Royalty Agreements


On July 1, 2008, our wholly owned subsidiary entered into Patent Assignment Agreements with two parties, our President and CEOas well as our former CEO/current CTO, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and CEOthese two individuals, have been assigned to the Company. In exchange, the Company agreed to pay a royalty of 5% of gross revenues to each of the CEO and Presidentthese two individuals for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assigned to Cavitation Technologies on May 13, 2010.


 The Company's CTO and President both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through June 30, 2012.

On April 30, 2008 (as amended November 22, 2010), our wholly owned subsidiary entered into an employment agreement with Varvara Grichko who became a memberthe Director of the Board of Directors in September 2010. Mrs. GrichkoChemical and Analytical Department (the "Inventor")who shall receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which Mrs. Grichkothe Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year.

6

37



As

Licensing Agreement

On May 14, 2012, we signed a 3-yearR and D, Marketing and Technology License Agreement (the "Agreement")with n.v. Desmet Ballestra Group, s.a. ("Desmet"). The Agreement provides Desmet (licensee) an exclusive license and right to develop, design and supply systems which incorporate Nano Reactor® devices on a global basis but limited to oils and fats and oleo chemical applications. CTi (licensor) remains owner of the current patents and patent applications but Desmet will be co-owner of any new process patent applications jointly developed. Desmet has agreed to provide limited monthly advance payments on future sales to CTi, if necessary. Payments made by Desmet during fiscal 2012 amounted to $125,000. Desmet shall be entitled to immediately terminate the present agreement in case the claims of current US Patent Application Number 12/484,981 are not granted as such or are cancelled. In addition, Desmet may terminate the agreement on August 1 of any particular year if they have not installed at least 6 Nano Reactor® devices in the previous 12 month period. CTi may terminate the Agreement for material default. This Agreement supersedes a previous agreement dated November 1, 2010, amended on June 30, 2010,1, 2011 and on September 2, 2011.

Note 13 - Subsequent Events

On December 6, 2011 we had notissued a convertible promissory note payable to the Prolific Group, LLC, in the amount of $25,000 with an interest rate of 6% p.a. and due December 6, 2012. During June 2012, a conversion request was submitted for $21,450 corresponding to 1,500,000 shares. These shares were subsequently returned to the Company in the first quarter of fiscal 2013, and the note was paid any amounts relatedin full including a pre-payment premium of $12,500. On December 6, 2011 we issued a convertible promissory note payable to these royalties.


Employees

We have four totalthe Tripod Group, LLC, in the amount of $30,000 with an interest rate of 6% p.a. and full-time employeesdue December 6, 2012. During the first quarter of fiscal 2013, the note was paid in full including a pre-payment premium of $15,000.

On July 12, 2012 we entered into a convertible promissory note with Asher Enterprises, Inc. under which we issued a $53,000 convertible promissory note. The note is due April 13, 2013 and have engaged approximately 40 consultants and independent contractors overbears interest at 8% p.a. The note is convertible into shares of our common stock at a conversion price equal to 60% of the past two years. We work closely with employees and consultants comprisedaverage of experienced professionals who are chemists, civil, chemical, and mechanical engineers with expertise in hydrodynamic cavitation, nano technology, water treatment, and biotechnology. These individuals hold Ph.Ds in Chemistry and Biology as well as degrees in Civil, Chemical, and Mechanical Engineering.


We are a public company with stock tradedthe lowest three (3) Trading Prices for the Common Stock during the ten Trading Day period ending on the Overlatest complete Trading Day prior to the Counter Bulletin Board with ticker symbol CVAT. Our stock is also tradedConversion Date. The note was issued in reliance on Section 4(2) of the Berlin and Stuttgart Stock ExchangesSecurities Act of 1933. The note was not offered via general solicitation to the public. No sales commissions or other remuneration was paid in connection with the symbol WTC. Our single location is our headquarters in Chatsworth, CA.

Item 9A(T).issuance of this note.

ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A.  CONTROLS AND PROCEDURES

Disclosure Controls and Procedures


Report of Management on Internal Control over Financial Reporting

The Company’s

In accordance with rule 13a-15(a), CTi management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act. Our management has evaluated, under the supervision and with the participation of our chief executive officer and chief financial officer, the effectiveness of ourmust maintain disclosure controls and procedures as defined in Rule 13a-15(e) of the end of the period covered by this report pursuant to Rule 13a-15(b) under the Securities and Exchange Act of 1934, (“or the Exchange Act”). Based on that evaluation, our chief executive officer and chief financial officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuringAct, to provide reasonable assurance that information required to be disclosed by the Company in ourreports that it files or submits under the Exchange Act reports is (1) recorded, processed, and summarized and reported within the time periods specified in the Securities and Exchange Commission’sCommission rules and forms, and (2) accumulated and communicated to ourthe Company's management, including our chiefits principal executive officer and chiefprincipal financial officer, as appropriate to allow timely decisions regarding required disclosure.


Our Principal Executive Officer

In accordance with Rule 13a-15(b) and Principal Financial Officer do not expect that our(c), management must also evaluate the effectiveness of these disclosure control and procedures at the end of each fiscal year. As of June 30, 2012, the Company carried out an evaluation, under the supervision and with the participation of its principal executive officer and principal financial officer, of the effectiveness of the design and operation of the Company's disclosure controls or internal controls will prevent all error and all fraud. Although ourprocedures. Based upon that evaluation, the Company's principal executive officer and principal financial officer concluded that these disclosure controls and procedures were designed to provide reasonable assuranceeffective as of achieving their objectivesJune 30, 2012.

38


Report of Management on Internal Control over Financial Reporting

Management is responsible for establishing and our principal executive and financial officer have determined that our disclosure controls and procedures are effective at doing so at that reasonable assurance level, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake.


We have included the entire definition ofmaintaining adequate internal control over financial reporting as set forthdefined in Exchange Act Rule 13a-15(f) as follows:under the Exchange Act. The Company’sCompany's internal control over financial reporting is designed under the supervision of our principal executive and principal financial officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’sCompany's assets;

7


(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that the Company’sCompany's receipts and expenditures are being made only in accordance with authorizations of the Company’sCompany's management and directors; and


(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’sCompany's assets that could have a material effect on the financial statements.Furthermore, smaller reporting companies face additional limitations. Smaller reporting companies employ fewer individuals and find it difficult to properly segregate duties. Often, one or two individuals control every aspectstatements.

In accordance Rule 13a-15(c), as of the Company's operation and are in a position to override any systemend of each fiscal year, management must evaluate the effectiveness of internal control.


In assessingcontrol over financial reporting. Under the supervision and with the participation of our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting we useas of June 30, 2012. We evaluated the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”("COSO") inInternal Control - Integrated Framework. Based on our assessment using thosethese criteria, under the supervision and with the participation of our management including our principal executive officer and principal financial officer, we concluded that for the period ending June 30, 2010, our internal controlscontrol over financial reporting was effective as of June 30, 2012.

Changes in Internal Control over Financial Reporting

There have been no changes in the Company's internal control over financial reporting during the quarter ended June 30, 2012 that materially affected, or are effective.

Thisreasonably likely to materially affect, the Company's internal control over financial reporting.

Attestation

Pursuant to Item 308(b) of Regulation S-K, as amended by the Dodd-Frank Wall Street Reform and Consumer Protection Act (Wall Street Reform Act), this report does not include an attestation report of the Company’sCompany's registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to the new FinancialThe Wall Street Reform bill enacted in July 2010 whichAct permanently exempts non-accelerated filers such as our companysmall public companies from the requirement to provide only management’s report in this annual report.


Changes in Internal Control over Financial Reporting

Our conclusion aboutobtain an external audit on the effectiveness of internal financial reporting controls.

ITEM 9B.  Other Information

Nothing to report.

39


Part III

ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

Person

Age

Position

Todd Zelek

55

CEO, Secretary & Director

Igor Gorodnitsky

52

President & Director

R.L. Hartshorn

64

CFO and Director

Varvara Grichko

55

Director

James Fuller

71

Director

Audit committee standing members consist of Todd Zelek, James Fuller, and R.L. Hartshorn. We anticipate forming compensation, governance, and other committees as necessary.

Todd Zelek. Mr. Zelek has been our Internal ControlsChairman and CEO since June 14, 2011. Prior to joining the Company, Mr. Zelek was formerly a private investor and former Investment Banker. Mr. Zelek was formerly Managing Director, Internet Group Head and Co-Head of the Los Angeles Investment Banking office for Lehman Brother, Inc. from 1995 through 2001. Prior to that he was a Managing Director and head of the Thrift Industry practice at Salomon Brothers in Los Angeles and New York. He began his career as an Investment Banker at Smith Barney in 1982. Mr. Zelek earned a Master's degree from the Sloan School at MIT in 1982 and graduated with Distinction from Cornell University in 1979. He was a member of Phi Beta. Mr. Zelek is an Independent Director of AgFeed Industries, Inc.

Igor Gorodnitsky.  Mr. Gorodnitsky has been our President and member of the Board of Directors since September 26, 2008. Mr. Gorodnitsky developed expertise in handling and processing hazardous waste material. As a Senior Haz-Mat Specialist, he coordinated and successfully completed more than 500 emergency response Haz-mat clean-ups over the past 20 years. He coordinated and supervised Haz Mat projects, emergency and routine spill clean-ups, and confined space entry tasks. He coordinated and scheduled manpower and purchased and scheduled equipment and materials for containment and treatment of spills. He successfully managed, coordinated and supervised projects including Hazscanning, sampling, lab-packing, manifesting, profiling, labeling, and other special procedures for a variety of commercial clients  and municipalities. He is a chemist by training and holds numerous certifications and licenses including Hazwoper Training Program, Confined Space Entry and Gas Vapour HazCating, Certified Uniform Waste Manifest Training, Basic and Intermediate HazCating, On-Scene Incident Commander Emergency, Site Remediation Methods, Underground Storage Tank Removal, Health & Safety Supervisor Certification, Hazardous Certification, and Tosco Refinery Safety. Mr. Gorodnitsky was president of Express Environmental Corp. since its inception in 1980 until he sold his interest in January 2009.

R.L. Hartshorn.  Mr. Hartshorn has served as Chief Financial Reporting changedOfficer and member of the Board of Directors of the Company since September 26, 2008.  He previously served as a consultant to the company beginning in December 2007.  He served 15 years in a variety of leadership and operational positions in international banking with Chase Manhattan, the Swiss National bank (Foundation) and other banks in Europe, New York, and Latin America.  He speaks German, Portuguese, and Spanish. As a vice president at Chase and other banks, he was largely responsible for cultivating credit and marketing relationships with corporate clients across a variety of industries. He also held sales and sales management positions including seven years as Marketing & International Sales Manager for a software and advertising company.  Overall, Mr. Hartshorn's operational experience includes 13 years with a sales quota and seven years with P&L responsibility. He has been involved in the start-up of four business units and a turn-around of a business unit. He earned a B.S from “ineffective” to “effective” as we implemented internal controls which we evaluated as working properlytheU.S. Naval Academy in 1971and an MBA fromThe Thunderbird School of Global Management in 1977.

40


James Fuller. Mr. Fuller is an independent director, and effectively. Changes to our design and operationshas been Chairman of our controls primarily relatedAudit Committee and Independent Financial Expert since February, 2010. He was formerly a Vice President of the New York Stock Exchange and director of the Securities Investor Protection Corporation. In addition to his over 30 years experience in the increased usesecurities markets, Mr. Fuller sat on the Board of outside consultantsTrustees of the University of California, Santa Cruz and implementationpreviously served as Chairman of new internal control procedures.


Steps we have taken include:

a. Withtheir Audit Committee and Independent Financial Expert.  Jim is a partner at Baytree Capital Associates, LLC. He received his BS in Political Science from San Jose State University and his MBA from California State University- Fresno.

Varvara Grichko.  Dr. Grichko has been a member of our Board of Directors since September, 2010. She is currently Director of R&D for the assistanceCompany. She received her B.S./M.S degree in Chemistry from Novosibirsk State University in Russia, and earned her Ph.D. in Chemistry from the Russian Academy of Science and her Ph.D. in Biology from the University of Waterloo in Canada. Dr. Grichko worked at the Institute of Inorganic Chemistry of the Siberian Branch of the Russian Academy of Science, Marquette University and Novozymes, and was the co-founder of Nanolytics, Inc. She is author of numerous patents and scientific publications.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our executive officers, directors, persons who own more than 10% of our common stock, and immediate family members living in the same household to file an outside consultant, we were ableInitial Statement of Beneficial Ownership on Form 3 and changes in ownership on Form 4 with the Securities and Exchange Commission (the "SEC"). Such "insiders" are required by SEC rules to design, implement, and test processes and procedures for Internal Controls over Financial Reporting.


b. With the helpfurnish us with copies of another outside consultant, we were able to raise our knowledge and expertise of GAAP to a level that is consistent with our conclusion that our internal controls are effective.

c. We updated and implemented new internal control procedures which address our risk assessment process, entity level control evaluations, and testing of key controls over financial reporting.

d. We continue to monitor our internal control processes and proceduresall Section 16(a) forms they file.

Based on a regular basis


Part III

Item 10review of Forms 3, 4, and 5 and amendments thereto furnished to us during fiscal 2012 ended June 30, 2012, the following delinquent filings were filed: Todd Zelek CEO, submitted one delinquent Form 3 and one delinquent Form 4 involving two transactions. James Fuller, Director, submitted one delinquent Form 4 involving three transactions. Varvara Grichko, member of the Board of Directors Officers, and Corporate Governance

Director of Research and Development for the Company, did not file one delinquent Form 4 involving four transactions.

Filing delinquencies from previous years included: R.L. Hartshorn, CFO and Board Member, filed one delinquent Form 4 relating to seven transactions. Igor Gorodnitsky, President and Director, filed one delinquent Form 4 involving two transactions. Roman Gordon, Chief Technology Officer and beneficial owner of more than 10% of the common stock, filed one delinquent Form 4 involving two transactions. James Fuller, Director, filed one delinquent Form 3 and one delinquent Form 4 involving six transactions. Varvara Grichko, member of the Board of Directors and Director or Research and Development for the Company, did not file one delinquent Form 3 and a Form 4 involving five transactions.

Code of Ethics


The Company has not yet

We have adopted a Code of Business Conduct and Ethics duethat applies to among other things, its continuing search for qualified outsideall officers, directors and committee members. The Company expects it will adoptemployees. A copy may also be obtained free of charge by mailing a request in writing to: Cavitation Technologies, Inc., 10019 Canoga Ave., Chatsworth, CA 91311 USA. If we make any substantive amendments to the Code of Business Conduct and Ethics prioror grant any waiver from a provision of the Code to its next annual filingany executive officer or director, we will promptly disclose the nature of the amendment or waiver in a current report on Form 10-K and will undertake in such Form 10-K filed with the Commission to provide any person without charge, upon request, a copy of such code of ethics and explain the manner in which such request may be made.

8
8-K.

41



Item

ITEM 11.  EXECUTIVE COMPENSATION

Executive Compensation


The following table summarizes the compensation earned by each named executive officer of the Company for the past two fiscal years determined on the basis of rules adopted by the SEC relating to smaller reporting companies.

                 Non-Equity Non-Qualified All   
           Stock  Option  Incentive Plan Deferred Other   
  Year  Salary  Bonus  Awards (1)  Awards  Compensation Compensation Compensation  Totals
Todd J. Zelek * 2012 $97,500 (1)$46,290 (2)   $272,601 (3)$-  $-  $-   $409,038 
Chief Executive Officer 2011 $-   $-    -   $-   $-  $-  $-   $-  
                         
Igor Gorodnitsky 2012 $146,250 (4)$     $-   $-  $-  $-   $146,250 
President 2011 $195,000 (4)$-    -   $-   $-  $-  $-   $195,000 
                         
R.L. Hartshorn 2012 $60,000 (5)$-    -   $-   $-  $-  $-   $60,000 
Chief Financial Officer 2011 $56,250 (5)$-    -   $-   $-  $-  $-   $56,250 

(1) For the year ended June 30, 2012, Mr. Zelek earned a base salary of $97,500 none ofwhich was paid in cash

              Non-Equity  Non-Qualified  All    
       Stock  Option  Incentive Plan  Deferred  Other    
  Year Salary  Awards (2)  Awards  Compensation  Compensation  Compensation  Totals 
Roman Gordon 2010 $195,000  $800,000(3) $-  $-  $-  $-  $995,000 
Chief Executive Officer 2009 $172,857  $-  $-  $-  $-  $-  $172,857 
                               
Igor Gorodnitsky 2010 $195,000(1) $800,000(4) $-  $-  $-  $-  $995,000 
President 2009 $172,857(1) $-  $-  $-  $-  $-  $172,857 
                               
R.L. Hartshorn 2010 $-  $263,750(5) $-  $-  $-  $-  $263,750 
Chief Financial Officer 2009 $-  $184,349(5) $29,585(6) $-  $-  $-  $213,934 
     and all of which was recorded as accrued payroll as of June 30, 2012. Total accrued salary for Mr. Zelek at June
(1)In 2009, Mr. Gorodnitsky earned a salary of $172,857.  On June 1, 2010, the Company issued a note payable to Mr. Gorodnitsky in the amount of $278,922 as payment for all deferred salary amounts owed to him for services provided through November 30, 2009.  During 2010, Mr. Gorodnitsky earned a salary of $195,000, of which a total of $49,152 was unpaid and recorded as accrued payroll as of June 30, 2010.
(2)
Stock awards are disclosed at the expense recorded based on their aggregate grant date fair values as calculated under ASC 718, Share-Based Payment.  All share amounts disclosed include the impact of a 3 for 1 forward stock split which was effective as of October 29, 2009.
(3)In July 2009, the Company issued Mr. Gordon 3,000,000 shares of restricted common stock as payment for services.  On the date of grant, the shares had an aggregate fair value of $800,000.  The shares vest through January 2, 2011 and are being expensed in the financial statements over that time.  During the year ended June 30, 2010, the Company recorded a total of $521,673 of expense associated with this grant.  The remaining $278,327 will be recorded over the vesting term during the year ended June 30, 2011.
(4)In July 2009, the Company issued Mr. Gorodnitsky 3,000,000 shares of restricted common stock as payment for services.  On the date of grant, the shares had an aggregate fair value of $800,000.  The shares vest through January 2, 2011 and are being expensed in the financial statements over that time.  During the year ended June 30, 2010, the Company recorded a total of $521,673 of expense associated with this grant.  The remaining $278,327 will be recorded over the vesting term during the year ended June 30, 2011.
(5)In July 2009, the Company issued Mr.  Hartshorn 750,000 shares of restricted common stock as payment for services.  On the date of grant, the shares had an aggregate fair value of $200,000.  The shares vest through January 2, 2011 and are being expensed in the financial statements over that time.  During the year ended June 30, 2010, the Company recorded a total of $130,418 of expense associated with this grant.  The remaining $69,582 will be recorded over the vesting term during the year ended June 30, 2011.  In addition, as compensation during the year ended June 30, 2010, Mr. Hartshorn was also issued an aggregate total of 350,000 shares of common stock with an aggregate grant date fair value of $63,750.  During the year ended June 30, 2009, Mr. Hartshorn was issued an aggregate total of 402,000 shares of common stock with an aggregate grant date fair value of $184,349.
9
     30, 2012 amounted to $167,500.

(2) During 2012, Mr. Zelek received two million shares of stock valued at $46,290 as part of an employment
     agreement that was still being negotiated at June 30, 2012. No compensation was received in fiscal 2011 which
     ended June 30, 2011. Stock awards are disclosed at the aggregate grant date fair values as calculated under ASC
     718, Share-Based Payments. Assumptions made in valuing stock options are included in Note 10 the Financial
     Statements - "Stockholder's Equity".

(3) During fiscal 2012, Mr. Zelek received 10,000,000 stock options half of which vested immediately and half of
     which vest in one year. Option Awards are reported at the aggregate grant date fair value computed in
     accordance with ASC 718.

(4) For the year ended June 30, 2011, Mr. Gorodnitsky earned a base salary of $195,000 but received only $157,500
     in cash with the remaining $37,500 recorded as Accrued Payroll at June 30, 2011. For the year ended June 30,
     2012, Mr. Gorodnitsky earned a base salary of $146,250 none of which was paid in cash and all of which was
     recorded as accrued payroll as of June 30, 2012. Total accrued salary for Mr. Gorodnitsky at June 30, 2012
     amounted to $227,798.

(5) For the year ended June 30, 2011, Mr. Hartshorn received an aggregate total of 375,000 shares of common stock
     with an aggregate grant date fair value of $56,250 as compensation. For the year ended June 30, 2012, Mr.
     Hartshorn earned a base salary of $60,000 none of which was paid in cash and all of which was recorded as
     accrued payroll as of June 30, 2012. Total accrued salary for Mr. Hartshorn at June 30, 2012 amounted to
     $100,000.

Messrs Zelek, Gorodnitsky, and Hartshorn also served as members of the Board of Directors during fiscal 2012 and part of their compensation was received for services provided as a board member.

42


Outstanding Equity Awards at Fiscal Year-End

The following table shows outstanding equity-based awards that were held by executive officers as of June 30, 2012.

  Option Awards  Stock Awards
      Equity        Equity Equity Incentive
      Incentive      Market Incentive Plan Awards:
  Number Number Plan Awards      value of Plan Awards market or
  of securities of securities # of Securities    # of Shares Shares # of Unearned payout value of
  Underlying Underlying underlying    or units of or units of Shares, units unearned shares,
  Unexercised Unexercised Unexercised OptionOption stock that stock that or other units or other
  Options Options Unearned Exerciseexpiration have not have not rights that rights that have
Name # Exercisable # Unexercisable Options Pricedate vested vested have not vested not vested
                  
Todd J. Zelek  5,000,000 5,000,000  -   $ 0.03 2/16/2022 -   $ -  -   $ - 
Chief Executive Officer                 
                  
Igor Gorodnitsky -   -   -   $ -  -   3,000,000  $ 90,000  -   $ - 
President                 
                  
R.L. Hartshorn 102,366 $ -  -   $ 0.67 8/31/2016 $ -    -   $ - 
Chief Financial Officer 71655     $ 0.33 8/31/2016        

We do not offer retirement benefit plans to our executive officers.

Compensation of Directors

The following table sets forth certain information with respect to the compensation paid to our directors for fiscal 2012 determined on the basis of rules adopted by the SEC relating to smaller reporting companies.

  Fees     Non-equity      
  Earned     inventive Non-qualified    
  or paid Stock Option plan deferred All other  
  in cash Awards Awards compensation compensation compensation Total
Name ($) ($) ($) ($) Earnings ($) ($)
               
James Fuller (1) -   $ 4,051  $ 14,101  $ -   $ -   $ -   $ 18,152 
Varvara Grichko (2) -   $ 386  $ -  $ -   $ -   $ -   $ 386 

(1) In fiscal 2012, Mr. Fuller received an aggregate 112,500 shares of common stock with a grant date fair

(6)On July 21, 2008, Mr. Harshorn was granted 71,655 and 102,366 stock options to purchase shares of our common stock with an exercise price of $0.33 and $.67 per share, respectively.  The grant date fair value of these options amounted to $29,585.
     value of $4,051. Mr. Fuller also received 500,000 options that vest over three years. Awards of options are
Item     reported at the aggregate grant date fair value computed in accordance with ASC Topic 718 and were value at
     $14,101. Mr. Fuller is the Company's Audit Committee Chairman and Independent Financial Expert. His total
     outstanding stock and option awards at June 30, 2012 amounted to 337,500 and 500,000 respectively.

(2) In fiscal 2012, for services as Director, Ms. Grichko received 10,000 shares of common stock with
     a grant date fair value of $386. She also received 35,000 shares for services related to Director of R&D.
     Her accrued salary as Director of R&D for the Company at June 30, 2012 was $96,000. Ms. Grichko's total outstanding
     stock and option awards at June 30, 2012 amounted to 490,183 and 1,520,600 respectively .

43


ITEM 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information concerning the number of shares of our common stock known by us to be owned beneficially as of June 30, 2012 and the date hereof by: (i) each person (including any group) that owns more than 5% of any class of the voting securities of our company; (ii) each director and officer of our company; and (iii) directors and officers as a group. Unless otherwise indicated, the stockholders listed possess sole voting and investment power with respect to the shares shown. The address for all directors and officers, unless otherwise indicated, is 10019 Canoga Avenue, Chatsworth, CA 91311. 

       Amount and    
       Nature of    
    Title of  Beneficial  Percent of 
Name of Beneficial Owner   Class  Ownership  Class (1) 
Todd J. Zelek *   Common Stock   2,000,000   1.2%(2)
Chief Executive Officer and Chairman of the Board           
            
Igor Gorodnitsky   Common Stock   20,323,475   12.0% 
President           
            
R.L. Hartshorn   Common Stock   1,877,366   1.1%(3)
Chief Financial Officer           
            
James Fuller   Common Stock   337,500   * 
Chairman of Audit Committee           
            
Varvara Grichko   Common Stock   490,183   *(4)
Director           
            
Roman Gordon   Common Stock   20,323,475   12.0%(5)
Chief Technology Officer           
            
BioWorld Management LTD   Common Stock   9,500,000   5.6% 
            
Directors and Officers   Common Stock   23,028,524   14.8% 
(as a group, five individuals)           

* Less than 1%

(1) Based on 168,782,063 issued and outstanding shares of common stock as of June 30, 2012.

(2) In addition, Mr. Zelek has the right to acquire 5,000,000 shares of common stock through stock options.

(3) In addition, Mr. Hartshorn has the right to acquire 174.021 shares of common stock through stock options.

(4) In addition, Dr. Grichko has the right to acquire 1,520,600 shares of common stock through stock options. Dr. Grichko is alsoDirector of R&D for the Company.

(5) Mr. Gordon is neither a director nor an officer of the Company but he is owner of more than 10% of the outstanding stock.

For details regarding stock options, please refer toNotes to the Financial Statements - Note 10 Stockholder's Equity.

44


ITEM 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

Certain Relationships and Related Party Transactions and Director Independence.


Other than compensation agreements and other arrangements with our executive officers and directors and the transactions described below, during our last two fiscal years, there has not been, and there is not currently proposed, any transaction or series of similar transactions to which we were or will be a party in which the amount involved exceeded or will exceed the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal years and in which any of our directors, executive officers, holders of more than five percent of any class of our voting securities or any member of the immediate family of the foregoing persons had or will have a direct or indirect material interest.


In accordance with item 404 (a)Regulation S-K 404(d) for Smaller Reporting Companies, we provide information for the last two fiscal years.

Related Party Payables

On December 27, 2011 the Company's CEO, Todd Zelek, extended to the Company a short term loan due on demand of regulation S-K,$100,000 at an annual interest rate of 12%. At June 30, 2012, the outstanding balance remained $100,000 along with $6,000 in accrued interest.

During fiscal 2012, the Company provided a $15,000 advance against future reimbursable company has had noexpenses to our President and Board Member, Igor Gorodnitsky. This amount was subsequently used and the outstanding balance on June 30, 2012 was $0. The Company provided an advance against future reimbursable company expenses of $15,000 to Roman Gordon, Chief Technology Officer, sibling of Igor Gorodnitsky, and owner of more than 5% of the outstanding common stock. The outstanding balance at June 30, 2012 was $15,000.

During the course of fiscal 2012, various affiliates incurred expenses on behalf of the company. The outstanding balance at June 30, 2012 was $59,608 but this amount was reduced to less than $10,000 as of the date of this filing.

Refer to Footnote 8,Related Party Short-Term Loan and Payables, and Note 12,Commitments and Contingencies,Royalty Agreements, for a description of related party transactions with our executive officers during the fiscal yearsyear ended June 30, 2010 or 2009, with the exception that:


On July 1, 2008, our wholly owned subsidiary entered into Patent Assignment Agreements with our President and CEO where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and CEO have been assigned to the Company. In exchange, the Company agreed to pay a royalty of 5% of gross revenues to each of the CEO and President generated from licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assigned to Cavitation Technologies on May 13, 2010.

On April 30, 2008 our wholly owned subsidiary entered into an employment agreement with Varvara Grichko who became a member of the Board of Directors in September 2010. Mrs. Grichko shall receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which Mrs. Grichko was the legally named inventor, and 3% of actual gross royalties received by the Company from the patent in each subsequent year.

2012.

Director Independence


As our common stock is currently traded on the OTC Bulletin Board, we are not subject to the rules of any national securities exchange which require that a majority of a listed company’scompany's directors and specified committees of the board of directors meet independence standards prescribed by such rules. For the purpose of preparing the disclosures in this Report on Form 10-K regarding director independence, we have used the definition of “independent director”"independent director" set forth in the Marketplace Rules of The NASDAQ, which defines an “independent director”"independent director" generally as a person other than an executive officer or employee of the Company or any other individual having a relationship which, in the opinion of the Company’sCompany's board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Consistent with these standards, we believe that James Fuller is an Independent Financial Expert and independent director.


45


ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

Audit

Our principal auditing firm is Rose, Snyder, and Jacobs.  During fiscal 2012 and 2011, we incurred expenses of $63,509 and $57,950 respectively for professional services rendered for the audit of our annual financial statements and review of quarterly financial statements included on Form 10-Q.

Tax Fees

The aggregate fees billed in fiscal 2012 and fiscal 2011 for professional services rendered by the principal accountant for tax preparation amounted to $10,600 and $10,300 respectively.

Audit Committee

The charter of the Audit Committee provides that the Audit Committee pre-approves all audit services and permitted non-audit services to be performed for CTi by its independent public accounting firm, subject to the de minimis exceptions for non-audit services described in Section 10A(i)(1)(B) of the Exchange Act. 

Part IV


ITEM 15.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES


(a) The following documents are filed as part of this annual report on Form 10-K:


1.Financial Statements

  1. Financial Statements
  2. The financial statements are filed as part of this report under Item 8 “Financial"Financial Statements and Supplementary Data”Data".

10


2.Financial Statement Schedules

  • Financial Statement Schedules
  • All other schedules are omitted because they are not applicable or the required information is presented in the financial statements and notes thereto.


    3.Exhibits

  • Exhibits
  • The exhibits required by Item 601 of Regulation S-K are included in Item 15(b) below.


    46


    (b) - Exhibits.

    11

    Exhibit FiledIncorporated by Reference
    NumberExhibit DescriptionHerewithFormPeriod EndedExhibitFiling Date
           
    3(i)(a)Articles of Incorporation - original name of Bioenergy, Inc. SB-2N/A3.1October 19, 2006
    3(i)(b)Articles of Incorporation - Amended and Restated 10-QDecember 31, 20083-1February 17, 2009
    3(i)( c )Articles of Incorporation - Amended and Restated 10-QJune 30, 20093-1May 14, 2009
    3(i)(d)Articles of Incorporation - Amended; increase in authorized shares 8KN/AN/AOctober 29, 2009
    3(i)(e)Articles of Incorporation - Certificate of Amendment; forward split 10QSeptember 30, 20093-1November 16, 2009
           
    10.1Patent Assignment Agreement between the Company and Roman Gordon dated July 1, 2008. 8KJune 30, 200910.1May 18, 2010
    10.2Patent Assignment Agreement between the Company and Igor Gorodnitsky dated July 1, 2008. 8KJune 30, 200910.2May 18, 2010
    10.3Assignment of Patent Assignment Agreement between the Company and Roman Gordon 8KJune 30, 200910.3May 18, 2010
    10.4Assignment of Patent Assignment Agreement between the Company and Igor Gorodnitsky 8KJune 30, 200910.4May 18, 2010
    10.5Employment Agreement between the Company and Roman Gordon date March 17, 2008 10K/AJune 30, 200910.3October 20, 2011
    10.6Employment Agreement between the Company and Igor Gorodnitsky dated March 17, 2008 10K/AJune 30, 200910.4October 20, 2011
    10.7Employment Agreement with R.L. Hartshorn datedSept. 22, 2009 10-QDecember 31, 201110.70February 10, 2012
    10.8Employment and Confidentiality and Invention Assignment Agreement between the Company and Varvara Grichko dated April 30, 2008 10-QDecember 31, 201010.3February 11, 2011
    10.9Board of Director Agreement - James Fuller 10-QDecember 31, 201110.12October 20, 2011
    10.10Technology and License Agreement with Desmet Ballestra dated 14 May 2012X    
    10.11Short Term Loan Agreement - CEOX    
    10.13Convertible Note Payable - Prolific Group LLC - $25,000 10-QDecember 31, 201110.40February 10, 2012
    10.14Convertible Note Payable - Tripod Group LLC - $30,000 10-QDecember 31, 201110.41February 10, 2012
    10.15Loan Agreement - Desmet Ballestra - Oct. 26, 2010 10-QDecember 31, 201110.43February 10, 2012
    14.1Code of Business Conduct and Ethics* 10-KJune 30, 201114.1September 28, 2011
    31.1Certificate of Principal Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002X    
    31.2Certificate of Principal Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002X    
    32.1Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adoptedX    
     pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.     
    32.2Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adoptedX    
     pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.     
           
    101.INS**XBRL Instance DocumentX    
    101.SCH**XBRL Taxonomy Extension SchemaX    
    101.CAL**XBRL Taxonomy Extension Calculation LinkbaseX    
    101.DEF**XBRL Taxonomy Extension Definition LinkbaseX    
    101.LAB**XBRL Taxonomy Extension Label LinkbaseX    
    101.PRE**XBRL Taxonomy Extension Presentation LinkbaseX    
           
    *In accordance with Regulation S-K 406 of the Securities Act of 1934, we undertake to provide to any person     
     without charge, upon request, a copy of our "Code of Business Conduct and Ethics". A copy may be requested     
     by sending an email to info@cavitationtechnologies.com.     
           
    **Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a     
     registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section     
     18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.     

    (c) - Financial Statement Schedules

    See Item (a) 2 above.

    47



            Incorporated by Reference
    Exhibit   Filed        
    Number Exhibit Description Herewith Form Pd. Ending Exhibit Filing Date
                 
    3(i)(a) Articles of Incorporation of Bio Energy, Inc.   SB-2 N/A 3.1 October 19, 2006
    3(i)(b) Articles of Incorporation - Amended and Restated   10-Q December 31, 2008 3.1 February 17, 2009
    3(i)(c) Articles of Incorporation - Amended and Restated   8-K N/A 3.1 May 14, 2009
    3(ii)(a) By-laws - originally Bioenergy, Inc.   SB-2 N/A 3.2 October 19, 2006
    2.01 Share Exchange Agreement between the Company and the shareholders of HydroDynamic Technology, Inc. dated October 22, 2008   8K N/A 2.01 October 24, 2008
                 
    10.1 Patent Assignment Agreement between the Company and Roman Gordon dated July 1, 2008.   10K/A June 30, 2009 10.1 October 20, 2011
    10.2 Patent Assignment Agreement between the Company and Igor Gorodnitsky dated July 1, 2008.   10K/A June 30, 2009 10.2 October 20, 2010
    10.3 Assignment of Patent Assignment Agreement between the Company and Roman Gordon   8K June 30, 2009 10.3 May 18, 2010
    10.4 Assignment of Patent Assignment Agreement between the Company and Igor Gorodnitsky   8K June 30, 2009 10.4 May 18, 2010
    10,.5 Employment Agreement between the Company and Roman Gordon date March 17, 2008   10K/A June 30, 2009 10.3 October 20, 2011
    10.6 Employment Agreement between the Company and Igor Gorodnitsky dated March 17, 2008   10K/A June 30, 2009 10.4 October 20, 2011
    10.7 Consulting Agreement between the Company and R.L. Hartshorn dated September 22, 2009 X        
    10.8 Employment and Confidentiality and Invention Assignment Agreement between the Company and Varvara Grichko dated April 30, 2008   10K/A June 30, 2009 10.6 October 20, 2011
                 
    10.9 Line of Credit Agreement from Nat. Bank of Ca. - change in terms dated Aug 1, 2009 X        
    10.10 Line of Credit Agreement from Nat. Bank of Ca. - change in terms dated Aug 1, 2010 X        
                 
                 
    10.11 Convertible Note and Warrant Purchase Agreement between the Company and Lyudmila Yeschenko dated December 18, 2008   10K/A June 30, 2009 10.8 October 20, 2011
    10.12 Convertible Note and Warrant Purchase Agreement between the Company and Jeffrey Neustadt dated December 20, 2008   10K/A June 30, 2009 10.9 October 20, 2011
    10.13 Convertible Note and Warrant Purchase Agreement between the Company and Christopher Tucker dated December 20, 2008   10K/A June 30, 2009 10.10 October 20, 2011
    10.14 Convertible Note and Warrant Purchase Agreement between the Company and Barnhart Holdings Ltd dated February 11, 2009   10K/A June 30, 2009 10.11 October 20, 2011
    10.15 Convertible Note and Warrant Purchase Agreement between the Company and Mark Escalante dated February 19, 2009   10K/A June 30, 2009 10.12 October 20, 2011
    10.16 Convertible Note and Warrant Purchase Agreement between the Company and Erena Karakis dated January 29, 2009   10K/A June 30, 2009 10.13 October 20, 2011
                 
    10.17 Marketing and Collaboration Marketing Agreement between Company and Desmet Ballestra Group X        
    10.18 Memorandum of Understanding X        
                 
    10.19 Warrant Purchase Agreement between Company and Cheryl Berns dated July 15 2009 X        
    10.20 Common Stock and Warrant Purchase Agreement - G Electrical Service Co. September 28, 2009 X        
    10.21 Common Stock and Warrant Purchase Agreement - Suzahnna Tepper dated October 16, 2009 X        
    10.22 Common Stock and Warrant Purchase Agreement - Suzahnna Tepper dated October 16, 2009 X        
    10.23 Common Stock and Warrant Purchase Agreement - G Electrical Service Co. dated October 16, 2009 X        
    10.24 Common Stock and Warrant Purchase Agreement with Star Tech Electric Co. dated October 19, 2009 X        
    10.25 Common Stock and Warrant Purchase Agreement - G Electrical Service Co. dated November 4, 2009 X        
    10.26 Common Stock and Warrant Purchase Agreement - G Electrical Service Co. dated November 17, 2009 X        
    10.27 Common Stock and Warrant Purchase Agreement - G Electrical Service Co. dated December 4, 2009 X        
    10.28 Common Stock and Warrant Purchase Agreement with Star Tech Electric Co. dated December 4, 2009 X        
    10.29 Common Stock and Warrant Purchase Agreement - Marina Vergilis dated February 4, 2010 X        
    10.30 Common Stock and Warrant Purchase Agreement - Undiscovered Equities, Inc. on February 11, 2010 X        
    10.31 Common Stock and Warrant Purchase Agreement with Star Tech Electric Co. on March 2, 2010 X        
    10.32 Common Stock and Warrant Purchase Agreement with G Electrical Service Co. on March 2, 2010 X        
    10.33 Common Stock and Warrant Purchase Agreement with Star Tech Electric Co. on March 2, 2010 X        
    10.34 Common Stock and Warrant Purchase Agreement with AM-PM Appliance Service on March 2, 2010 X        
    10.35 Common Stock and Warrant Purchase Agreement with Suzahnna Tepper June 1, 2010 X        
    10.36 Promissory Note - Anna Mosk dated January 11, 2010          
                 
    14.1 Code of Business Ethics X        
                 
    31.1 Certificate of Principal Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002 X        
    31.2 Certificate of Principal Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002 X        
    32.1 
    Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     X        
    32.2 
    Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     X        
    12


    SIGNATURES


    PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THIS REPORT HAS BEEN SIGNED BELOW BY THE FOLLOWING PERSONS ON BEHALF OF THE REGISTRANT AND IN THE CAPACITIES AND ON THE DATES INDICATED.


    INDICATED

    SIGNATURE TITLE DATE
         
    /s/ Todd ZelekIgor Gorodnitsky Chief Executive Officer and DirectorPresident; Member of Board of Directors October 20, 201112, 2012
    Todd ZelekIgor Gorodnitsky 
    (Principal Executive Officer)
    Chairman of the Board
      
         
    /s/ Igor GorodnitskyR.L. Hartshorn PresidentChief Financial Officer October 20, 201112, 2012
    Igor GorodnitskyR.L. Hartshorn (Principal Financial Officer)  
         
    /s/ R.L. HartshornJames Fuller ChiefAudit Committee Chairman, Independent Financial OfficerExpert October 20, 201112, 2012
    R.L. HartshornJames Fuller 
    (Principal Financial Officer and Accounting
    Officer)

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    Date: October 19, 2011Date: October 20, 2011
       
    By: /s/ Todd Zelek, Chief Executive OfficerBy: /s/ R.L. Hartshorn, Chief Financial Officer
    13

    48